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ABSTRACT 
Recent discoveries regarding the connection between changes to the human gut 
microbiome (GM) and the onset of various illnesses, especially those mediated by an 
autoimmune response, has led to interest in novel therapeutic methods to address such 
alterations. Targeted small molecule therapeutics could pave the way for phylum, genus, 
or even species-level population control of the GM in order to prevent undesirable changes 
that might promote disease onset. In pursuit of such treatments, the work presented in this 
dissertation demonstrates to use of small molecule amylase inhibitors to disrupt the starch 
utilization system (Sus) found in Bacteroides species, a common GM member belonging 
to the Bacteroidetes phylum, in a selective yet non-lethal manner.  
While a variety of small molecule amylase inhibitors were probed, acarbose 
showed consistent and drastic inhibition against multiple Bacteroides spp., including 
multiple strains of the clinically relevant species Bacteroides dorei. Inhibition was 
mediated through the disruption of Sus, depriving these bacteria of their primary metabolic 
energy source. Additionally, no serious adverse effects were noted against other common 
GM constituents. These factors highlight acarbose as a potent, selective, and non-lethal 
inhibitor of Sus-containing members of the GM. 
A mouse study was conducted with non-obese diabetic (NOD) mice treated with 
either a 10 µg/mL or  5 µg/mL dose of acarbose from 9 weeks to 28 weeks after birth to 
ascertain if the compound had any effects on the GM of a living organism. This mouse 
iii 
cohort is also a model for type 1 diabetes (T1D), an illness whose onset has been linked to 
shifts in GM members, so it was of interest if acarbose treatment would delay onset of the 
disease. Both shifts in GM composition and a small delays in the onset of diabetic 
symptoms were noticed in the 10 µg/mL dose cohort.  
In attempts to identify new small molecule inhibitors, synthetic alterations to the 
flavonoid quercetin were investigated. Quercetin has demonstrated a range of biological 
activities, including human amylase inhibition. Unfortunately its insolubility in water 
impedes use in many biological assays. To circumvent this, synthetic modifications were 
performed that successfully increased its solubility, and assays were performed against 
model GM organisms, though no Sus inhibitory properties were discovered. 
While the mechanism behind Sus mediated inhibition by acarbose is still under 
investigation and new small molecule inhibitors are being sought, the work presented here 
forms the basis for the use small molecule amylase inhibitors as therapeutics for dysbiosis 
mediated illnesses.  
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CHAPTER ONE: 
DEVELOPMENTS TOWARD TREATING GUT MICROBIOME DYSBIOSIS 
1.1 Human Gut Microbiome and Host Symbiosis 
The remarkable ability of microorganisms to adapt and thrive in even the most 
inhospitable environments has led to the colonization of practically every available surface 
in and on the human body. Tens of trillions of non-human cells call the human body home, 
meaning there is a roughly 1:1 ratio of human to non-human cells housed by our bodies 
that contribute to 0.3 % of a person’s body weight.1 Even spaces once thought to be sterile, 
such as the lungs, have been found to house small factions of microbes adapted to flourish 
in these restrictive environments.2–4 Evolving alongside their hosts, these organisms have 
formed symbiotic relationships, even conceptualized as an unconventional organ whose 
health and composition directly impacts the well-being of the host, and whose disruption 
may contribute to the development of various diseases and health complications. 
While this type of mutually beneficial relationship can be found in many locales in 
and on the body, one such microbiome that houses the largest contingent of non-self cells,1 
and thus highlights the interdependence between host and microbes, is found in the colon. 
The gut microbiome (GM) encompasses all bacteria, fungi, viruses, and other microscopic 
organisms found in the large intestines that have colonized the environment and established 
persistent communities. While the exact composition of this collective can vary based on 
1
a multitude of factors including health, diet, age, environment, etc.5–12, two phyla of 
bacteria dominate most healthy populations: the Bacteroidetes and the Firmicutes. In 
normal healthy westernized populaces, Firmicutes are the largest contributor with 
Bacteroidetes usually being the second largest and a minority of other microbes being 
present.5–7,13  
To thrive in the gut, organisms found there have evolved to rely on metabolites – 
primarily carbohydrates – that are taken in by the host that would normally pass through 
the intestinal tract unused without their intervention. While a majority of dietary 
polysaccharides ingested are subsequently degraded by human amylases into smaller oligo- 
and disaccharides that are then readily absorbed into the blood stream, some can make it 
to the colon and farther without being processed. Without intervention these undigested 
carbohydrates would then be excreted from the body as waste, but constituents of the GM 
have in turn come to capitalize on them as a primary energy source.  
To exploit these resources, members of this collective employ a wide variety of 
protein-mediated mechanisms that take advantage of these excess carbohydrates, either 
degrading polysaccharides into smaller components or seizing underutilized mono- and 
oligosaccharides.14–20 Specializations within the community have even developed, with 
different bacteria preferring specific carbohydrates based on size or composition in order 
to limit competition over resources.14,15,17,19 As a side benefit to the host, byproducts of 
these reactions can be absorbed by the colon, making up to roughly 10% of host caloric 
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intake.21 Other symbionts rely on host-derived glycans produced and shed by human cells 
to fuel their metabolic processes.22 
1.2 Benefits of a Thriving Microbiome to the Host 
This relationship between microbiome and host is mutually beneficial, with the 
microbes conferring a wide variety of favorable effects to the host in return. On a macro 
level, by inhabiting the colon and monopolizing the available resources and space, the GM 
prevent any transient pathogenic bacteria passing through the digestive tract from easily 
colonizing the colon. More specifically, various members of the GM interact with various 
host systems throughout the body, and are essential for both the training of the immune 
system as well as preserving the integrity of the gut epithelial layer that separates the blood 
stream from the interior of the colon.  
Bacterial processing of polysaccharides by GM members produces a variety of 
byproducts that can then be taken in and used throughout the body. Depending on both the 
organism and carbohydrate being fermented, a variety of such products are produced, 
predominantly the short chain fatty acids (SCFAs) butyrate, acetate, and propionate. 
Acetate and propionate, produced primarily by organisms in the Bacteroidetes phylum, 
have been shown to play roles in the gut-brain axis where they help regulate the production 
of various neuroendocrine components.23–26 SCFAs are also used as precursors in human 
metabolic pathways, such as gluco- and lipogenesis, carried out in the liver.27–32 Butyrate 
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is mostly obtained from the fermentation processes performed by members of the 
Firmicutes phylum and plays an integral role in maintaining the intestinal barrier between 
the lumen of the colon and the blood stream. The epithelial cells that comprise the lining 
of the intestines serve as a physical barrier preventing the passage of toxins, bacteria, or 
pathogenic compounds into the blood stream where they can impact the health of the host. 
This barrier is reinforced by tight junctions, a series of interlocking proteins that seal off 
the intercellular spaces between cells and preclude unregulated passage. Butyrate produced 
by colonic bacteria is taken in by the cells comprising this lining, inducing the  upregulation 
of AMP activated kinase, a regulator of protein assembly.33,34 AMP activated kinase is 
responsible for promoting the construction of individual proteins components into tight 
junctions, effectively plugging the space between cells. Through this interaction, the 
presence of butyrate-producing bacteria play a role in reinforcing host defenses against 
pathogenic invasion. 
GM members also assist in both training and maintenance of the innate immune 
system. The gut is colonized by bacteria at birth, and continually houses various 
populations throughout the host’s lifespan. Because of this, colonic microbiome 
constituents comprise some of the very earliest exposure of non-self cells to the immune 
system and therefore are essential for training of the host’s immune response to foreign 
cells.35 For instance, repeated exposure to bacterial components, such as Escherichia coli 
derived lipopolysaccharide (LPS) by the developing immune system promote tolerance of 
bacteria by the immune system. While the initial response is antagonistic, each subsequent 
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exposure elicits a more restrained response by the immune system until it “learns” to accept 
these non-human cells and no longer mounts severe immune responses in their 
presence.36-38 This training forms the basis for host tolerance towards beneficial 
communities, allowing them to thrive unmolested. Foreign microbes that have not 
participated in such learned responses are instead targeted by the immune system for 
elimination. 
Additionally, a range of antimicrobial compounds are produced by the GM 
constituents. These compounds are employed to prevent competition over similar 
resources, especially with microbes that have yet to establish a foothold in the colon. 
Multiple bacteria housed in the gut produce such compounds, and each employ a variety 
of configurations, protein domains, or structures leading to a diverse array of compounds 
that protect against the establishment of foreign microorganisms. The diversity in both the 
composition of these compounds and their targets has also led to the isolation and 
investigation of several of these agents as novel antibiotics for therapeutic use.39,40   
1.3 Dysbiosis and Disease 
Due to the variety of roles the GM plays in training, maintaining, and supporting 
various systems responsible for the well-being of the host, aberrations or changes to this 
community are thought to have potentially harmful effects on health. Such disruptions, 
termed dysbiosis, have been noted prior to or in conjunction with the appearance of several 
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illnesses such as both Type I41–44 and II45,46 diabetes, obesity,47–54 allergies,55–58 
inflammatory bowel disease,59–61 irritable bowel syndrome,62–64 cancer,65–67 autism,68,69 
and multiple sclerosis.70 While a causative mechanism for these observations has yet to be 
firmly established, evidence for these associations have continued to mount. One of the 
more heavily investigated connections is between gut microbiome dysbiosis and the 
development of autoimmune conditions. 
While the destruction of human cells carried out by the host’s own immune system 
that characterizes such conditions is facilitated through both an autoimmune response and 
genetic predispositions, these factors do not fully explain their manifestation. Indeed, 
children displaying such genetic predispositions do not always progress to clinical disease. 
Studies observing identical twins predisposed to type 1 diabetes (T1D) and other 
autoimmune conditions have also demonstrated that children with the same exact genetic 
backgrounds do not always both go on to develop the diseases, with one twin sometimes 
being symptomatic while the other is not.71 While the incidence of this difference has 
varied depending on the particular study, these observations suggest additional underlying 
environmental triggers that have yet to be identified leading to a search for other elements 
that could instigate or contribute to the development of such conditions. With the role the 
GM plays in both the training of the innate immune system as well as maintaining the 
intestinal barrier, disruptions to this system have been proposed as one such contributing 
factor.  
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While the development of early onset T1D is influenced by various genetic and 
environmental triggers, dysbiosis of the GM has consistently been implicated as one such 
factor. Investigations into the GM of infants genetically predisposed to the disease have 
consistently revealed a trend where children who would go on to present self-reactive 
immune markers displayed a dysbiosis where the relative abundance of the Bacteroidetes 
phyla population was elevated compared to those who did not.72–81 This trend has remained 
consistent in children from several countries across multiple continents in numerous 
studies.  
Several large scale studies, such as the Pathogenesis of Type 1 Diabetes – Testing 
the Hygiene Hypothesis (DIABIMMUNE) Project 78,82 covering Finland, Estonia, and 
Russia and The Environmental Determinants of Diabetes in the Young (TEDDY)83 Study 
covering the United States and Europe, tracked the development of the GM of hundreds of 
infants in multiple countries from a few weeks after birth to two or three years of age 
depending on the study. Microbiomes were analyzed through the use 16s rRNA sequencing 
of bacterial DNA present in stool samples in order to identify and track the development 
of infant GM population over the course of the respective studies. Again both of these 
studies identified a similar dysbiosis arising prior to onset of autoimmune markers, with an 
increase in members of the Bacteroidetes phyla. The DIABIMMUNE Project also revealed 
that regions with higher incidence of T1D also displayed a less diverse GM with an 
elevated population of members of the Bacteroides genus compared to regions that 
displayed lower incidence of the illness.36 Taken together, these studies highlight a 
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potential link in microbiota shifts and disease incidence that may contribute to the 
development of T1D in conjunction with genetic predisposition to the illness.   
Two potential hypotheses have emerged to explain these correlated shifts in 
microbial population prior to the development of an autoimmune response. Both rely upon 
the influence of the GM on training and maintaining host defenses from foreign agents. 
One such hypothesis, termed “leaky gut syndrome” (Figure 1.1), proposes that a shift in 
the GM population would in turn lead to a shift in the amount of metabolites produced by 
the GM and their availability in the environment, specifically SCFAs.44,84 An 
overabundance of members of the Bacteroidetes phylum could be enough of a shift in 
community composition to trigger an increase in acetate and propionate and consequently 
a drop in the relative amount of butyrate (i.e. the primary metabolite produced by 
Firmicutes) available in the colon. As described earlier, butyrate plays a crucial role in 
maintaining the integrity of tight junctions between epithelial cells lining the colon. 
Reduction in butyrate concentration, and the associated increase in gut permeability could 
open a pathway for foreign antigens to cross from the lumen of the colon into the blood 
stream, triggering an adverse immune reaction leading to the development of undesirable 
self-recognition and the eventual destruction of insulin producing beta cells by host defense 
systems. 
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Figure 1.1: Comparison of a healthy gut to one suffering from leaky gut syndrome. For a 
healthy gut, tight junctions (orange) between cells act as plugs, preventing antigen (green) 
passage from the lumen of the colon into the blood stream (red). If these tight junctions are 
compromised, as hypothesized by a drop in butyrate available in the colon, permeability of 
this barrier is increased allowing the passage of antigens through this barrier and initiating 
various disruptive effects. 
The second proposed route relies on the role GM members play in the training of 
the immune system’s response to non-self cells. In a paper released by the DIABIMMUNE 
Project in 2016,36 the authors described a difference in bacterial LPS exposure between 
European communities that displayed higher incidences of T1D in Finland and Estonia 
versus those in Russia that showed lower incidences. In Russia, children were primarily 
exposed to the LPS derived from Escherichia coli, which promotes healthy development 
of the innate immune system in the host. In contrast, children from Estonia and Finland 
had LPS exposure from a wider variety of bacteria, with a major contributor being those 
produced by several Bacteroides species, most notably Bacteroides dorei.36 
Drop in 
butyrate
Healthy Gut Leaky Gut 
Syndrome 
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LPS produced by Bacteroides spp. is structurally distinct from that produced by E. 
coli and demonstrated radically different abilities to promote the development of the innate 
immune system. Repeated exposure of E. coli derived LPS to immune components leads 
to a tolerance of the LPS, and therefore the associated bacteria.  This scenario ultimately 
results in a reduction in the production of antagonistic immune components. This learned 
tolerance of foreign cells through repeated exposure allows for the non-self cells in the 
body to then establish themselves without interference by the host. On the other hand, LPS 
produced by B. dorei did not display this ability, with repeated exposure continuing to elicit 
similar antagonistic immune responses therefore failing to impart beneficial tolerance as 
observed with E. coli.36 When LPS derived from both species are present, tolerance 
towards E. coli is also compromised, with the severity being dependent on the 
concentration of B. dorei LPS. This ability of the Bacteroides LPS to effectively disrupt 
the training of the innate immune system, even in the presence of beneficial LPS, is thought 
to contribute to the immune dysfunction that leads to the production of self-reactive 
components. This hypothesis was further supported by the DIABIMMUNE project when 
they introduce non-obese diabetic mice, a T1D murine model, to both forms of LPS.36 
Those given LPS derived from E. coli displayed a delay in the onset of disease markers, 
while those given B. dorei derived LPS did not.  
Beyond autoimmune diseases, shifts in human GM populations may play a role in 
exacerbating diseases affecting other systems of the body, including the neurological 
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system, as well as the hepatic system. Known as the Gut-Brain Axis, several aspects of the 
neuroendocrine system can be modulated and influenced by the metabolites of the GM, 
most notably through the SCFAs acetate and propionate.23–26 Disruptions of this system 
through loss of various SCFAs are thought to impact host health. Additionally liver disease 
and cirrhosis may be influenced by dysbiosis of the GM through the various associations 
and processes performed in the liver that are regulated and influenced by GM 
metabolites.85–88 
1.4 Targeting The HGM 
As the evidence for the link between dysbiosis of the GM and illness has increased, 
so too has interest in developing therapeutic methods designed to alleviate or prevent the 
onset of these shifts. Our understanding of how GM and illness are related is still growing, 
and the work presented here hopes to contribute to this underserved area of therapeutic 
investigations. The wide range of interactions between microorganisms with each other 
and the host present a unique set of challenges that must be considered  when developing 
a potential therapeutic method for targeting bacteria associated with these environments.  
As described above, diseases associated with the HGM are thought to be caused by 
either the overpopulation or under population of specific representatives of the community 
that under normal circumstances are either beneficial or benign to the host. Because of this, 
a strictly microbicidal approach is not ideal since such treatment could potentially eradicate 
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beneficial constituents along with the problematic offenders, leading to further fluctuations 
or losses that in turn cause a domino of unintended side effects. An alternative approach 
that instead induces a non-lethal form of grown inhibition might be more therapeutically 
advantageous. Specifically, a bacteriostatic strategy that would disrupt important, yet not 
critical, cellular systems in a target organism might lead to a retardation in the cell’s ability 
to grow and replicate in the competitive gut ecosystem, thus reducing their numbers in the 
community. Additionally, a non-lethal approach could lessen the selective pressure for the 
evolution of a resistant strain of the target compared to a more traditional bactericidal 
approach. 
The ability to target a specific microbial population is another desirable attribute 
for a potential therapy in order to avoid broad disruptions of the GM. If a treatment is not 
targeted, and multiple members are unintentionally suppressed, the protective effects of the 
GM could again be hindered, potentially resulting in further, undesired complications. 
Several studies have tried to identify disease-relevant microbial agents, either at the genus 
or species level, in order to devise treatments with an appropriate level of specificity in 
order to ensure maximal therapeutic impact with minimal risk of unintended side effects.  
1.5 Bacteroides, A Model Genus for Therapeutic Targeting 
As stated above, members of the Bacteroidetes phylum have been implicated as a 
potential causative agent in the development of autoimmune diseases, most notably T1D, 
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and for this reason my dissertation pursued a therapeutic intervention that might influence 
the growth of these microbes. Several investigations have been undertaken to identify the 
specific genus and species of organisms that play key roles in the onset of autoimmunity. 
One of the most influential of these studies was carried out by the DIABIMMUNE Project. 
As described previously, this project focused on tracking the HGM development of 
children predisposed to T1D from several European countries that had various rates of T1D 
incidence. While different aspects of this study have and will continue to be discussed 
throughout this work, one of the main trends identified was that an increase in the 
Bacteroides genus was seen prior to onset of illness, and was therefore cited as a potential 
contributor to the initial stages of disease development. In order to target members of the 
Bacteroides genus, we sought an ideal cellular target to inhibit with small molecules.   
In order to develop a non-lethal inhibition strategy, we sought a mechanism or 
metabolic process that was not essential for survival, but whose inhibition would impede 
the functions of the cell in a manner that cell reproduction and/or growth was hampered 
relative to other GM constituents. Members of the GM have developed a wide range of 
unique methods to harness and metabolize polysaccharides  in a competitive manner. Such 
differentiation not only allows for efficient use of resources, but also helps to limit the 
competition over similar carbohydrate substrates by multiple GM constituents. Because of 
the variety of unique methods employed, it was thought that a therapy could be devised 
that specifically targets the primary carbohydrate utilization systems unique to the 
Bacteroides genus. Inhibiting this system would force the bacteria to instead rely on less 
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efficient routes to obtain monosaccharides or other metabolites, thus leading to competition 
with bacteria better suited for their use, hopefully leading to the sought after impact on cell 
growth.  
Members of the Bacteroides genus are primarily starch utilizers, meaning that they 
preferentially uses glucose based polysaccharides in their metabolic processes.16 In order 
to do so, they have evolved a protein suite known as the starch utilization system (Sus) that 
specializes in the capture, degradation, and importation of glucose-based carbohydrates by 
the cell. While multiple species belonging to this genus possess various versions of Sus, 
the most well characterized Sus belongs to Bacteroides thetatiotaomicron (Bt) and is 
comprised of eight proteins that initiate and regulate such processes, SusABCDEFG and 
the TonB regulator (Figure 1.2).14,20,89 SusD, E and F are  responsible for recognition and 
capturing of starches present in the surrounding environment. Once brought to the cell 
surface, SusG, an amylase, hydrolyzes the polymeric starches in to smaller oligomers that 
are imported through the outer cell membrane by the porin, SusC. SusA and B, located in 
the intermembrane space, further degrade the oligomers into monomers and dimers that 
then pass through the inner membrane into the main body of the cell where they can be 
fermented as an energy source. The SusR regulator is activated in the presence of maltose, 
and upregulates the production of Sus components by the cell. Other members of this genus 
possess analogous systems that perform the same functions, though their exact composition 
may differ from the canonical Bt Sus. In addition to protein systems specific for starches, 
this genus contains a variety of other Sus-like systems that are selective for other classes 
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of polymeric carbohydrates, such as fructans and xylans, that can be utilized in the absence 
of the preferred starches.14,16 Both Sus and the various Sus-like constructs are regulated 
from polysaccharide utilization loci (PUL), discrete areas of the bacterial genomes that 
encode these systems. 
Figure 1.2: The canonical Sus as found in Bacteroides thetaiotaomicron, the most well 
characterized example. Comprised of Sus A, B, C, D, E, F and G along with the 
transcriptional regulator, SusR.  This and analogous Sus-like suites are the primary method 
for metabolite acquisition employed by this genus. 
For the purpose of identifying an inhibitory avenue, Sus makes an ideal platform to 
target. Disrupting its function would deprive the Bacteroides of the energy source they 
have evolved to preferentially rely upon, forcing them to instead forage for classes of 
carbohydrates are less available or that they are less suited to metabolize. This in turn would 
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hopefully lead to the Bacteroides competing against other GI microbes who are more suited 
to utilize these resources. This competition would then limit their metabolic process, and 
in turn their ability to grow. Ideally, selective non-lethal inhibition in this manner would 
allow for us to modify the population of Bacteroides in the gut by lowering their abundance 
in the GI tract. If there is a significant component in the development of diseases related to 
the increase in the Bacteroidetes phyla, such as those suggested by the studies described 
above, disruption of the Sus could be used to either correct their occurrence or, if caught 
early enough, prevent shifts prior to the development of the associated dysbiosis. While 
there are many other factors involved in the diseases associated with dysbiosis, including 
genetic risks, dietary and environmental factors, etc., guiding the GI microbiota in this 
manner could serve as a foundation for treatments addressing a major associated 
component in their development. This would be an especially effective form of treatment 
if aspects of the leaky gut and disruption of innate immune system training through shifts 
in bacterial LPS are verified to be responsible in part or in full in the development of 
autoimmune disorders.  
With Sus established as the targeted system, a method for inhibition became the 
initial focus of my dissertation. Several components of Sus could be targeted in principle, 
but one specific constituent was of particular interest. SusG belongs to a group of proteins 
known as amylases. This cohort is responsible for severing the glycosidic bonds that 
connect the individual sugars making up complex carbohydrates. Amylases are not unique 
to bacteria, with various plants and animals possessing analogous proteins in order to 
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breakdown the complex carbohydrates they obtain into more readily usable products. 
Human amylases are produced in both the salivary glands and pancreas and help 
breakdown dietary carbohydrates and are already the targets of several small molecule 
therapeutics used to treat Type 2 Diabetes. Compounds such as acarbose,90 miglitol,91 and 
voglibose90 inactivate human amylases, preventing the breakdown of complex 
carbohydrates into smaller sugars. These undigested sugars are then unable to pass into the 
circulatory system and raise blood glucose levels. It was hoped that if small molecule 
human amylase inhibitors were introduced to the Bacteroides that possess Sus, inhibition 
would be imparted on either the bacterial amylase, SusG, and/or other Sus components. 
This leads into the overarching hypothesis investigated in this work: can the 
introduction of human amylase inhibitors to starch utilizing Bacteroides spp. shut down 
the Sus, leading to inhibited growth in the presence of glucose-based polysaccharides in a 
selective manner exclusive to the genus. In support of this hypothesis, several levels of 
selective inhibition should be seen for an ideal small molecule inhibitor. At the lowest 
level, growth inhibition should be observed when Bacteroides are grown in the presence 
of starches, while no inhibition should be noted with the monosaccharide glucose. Growth 
in glucose demonstrates that the treatment is not inherently lethal to the bacteria. Inhibition 
of starch degradation, in addition to unhindered growth in glucose, would suggest the 
successful targeting of Sus since the only difference between successful growth and 
inhibited growth would be the carbohydrate available to the bacteria. Next, it would be 
important to investigate whether small molecule Sus inhibitors would show growth 
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inhibition in the presence polysaccharides that are metabolized by Sus-like suites.  The 
third level of inhibition would be to ensure that treatment does not affect members of the 
Firmicutes, the other main phyla found in the GI tract. Together these three levels of 
inhibition would provide significant support of the stated hypothesis, and offer a route 
toward the selective modification of the GI microbiome constituents as a therapeutic 
avenue in the treatment of illnesses initiated, either partially or in full, by dysbiosis of these 
populations. 
 Each chapter of this dissertation describes experiments that interrogated a different 
aspect of this hypothesis. Chapter two focuses on identifying successful inhibitors of Sus 
in model Bacteroides species using previously identified small molecule inhibitors of 
human amylases. Successful inhibitors were then probed against the Sus-like systems also 
belonging to Bacteroides as well as representative Firmicutes in order to establish 
selectivity. The following chapter then takes the most effective inhibitor from the previous 
chapter and analyses its efficiency on four strains of the clinically relevant species 
Bacteroides dorei. This organism has been correlated with increased incidences of T1D, 
and were isolated directly from patients with the condition. Chapter 4 details a mouse study 
using the non-obese diabetic (NOD) murine model that spontaneously develops beta cell 
autoimmunity that mimics T1D. Various doses of the most effective amylase inhibitor 
identified in chapter 2 were administered to mice from 9 weeks to 28 weeks after birth in 
order to see if treatment could alter composition of the GI microbiome and/or delays onset 
of the disease in treated mice. Finally, the last chapter describes organic modifications 
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performed on additional amylase inhibitors in order to increase their solubility. Initially 
these compounds were found to be completely insoluble in water, and therefore not suited 
for our assays. By adding functional groups that are easily ionizable, it was hypothesized 
that solubility would be increased to a point where they could be used in our experiments, 
and potentially reveal new inhibitor of Bacteroides possessing Sus. These modified 
compounds where then screened against our various representative bacteria in order to 
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EFFECTS OF ACARBOSE ON CARBOHYDRATE UTILIZATION BY 
BACTEROIDETES AND FIRMICUTES 
2.1 Introduction 
As described in the introductory chapter, the initial aim of this project was to disrupt 
the use of the starch utilization system (Sus) in order to deprive Bacteroides species of their 
primary energy source in the lower gut: starch-based polysaccharides. In order to 
accomplish this, various human α-amylase and glucosidase inhibitors where identified and 
probed for inhibitory properties. These compounds have previously demonstrated the 
ability to disrupt human amylases and glucosidases, and we hypothesized that compounds 
of this type might also exhibit inhibitory effects on the bacterial amylase, SusG, or 
potentially other Sus components. This would in turn interrupt the bacteria’s ability to 
process starches. The initial compounds screened can be broken into three groups:  
1) Small molecule glucosidase inhibitors used to treat type 2 diabetes (Figure 2.1)
Compounds investigated in this group include miglitol, voglibose, and acarbose, which are 
currently used to treat type 2 diabetes.1,2 All three are known to inhibit human amylases, 
disrupting the ability of the body to degrade starches into more easily absorbed mono- and 
oligosaccharides. Undigested starches then pass through the body without being absorbed 







bound to Sus components, specifically Sus G and Sus B.3,4 Interesting features shared 
among these three compounds is their structural similarity to carbohydrates or the direct 
incorporation of glucose into their structure.  
Figure 2.1: Structures the amylase inhibitors acarbose (II-1), voglibose (II-2), and miglitol 
(II-3) 
2) Flavonoids that exhibited inhibitory properties in vitro (Figure 2.2)
This class of compounds is isolated from multiple plant species, and in vitro studies 
have demonstrated that the flavonoid, quercetin, and its glucoside, rutin, can inhibit the 
breakdown of starches by amylases.5,6  























































3) Pseudosugar CS-1036 (Figure 2.3) CS-1036 is a compound that has also shown
inhibitory properties against the salivary amylases found in rat and monkey models.7 Like 
compounds described in category 1, CS-1036 also incorporates a carbohydrate into its 
structure. 
Figure 2.3: Structure of CS-1036 (II-6) 
A brief overview of assays conducted can be found below, while a more thorough 
procedure can be found at the end of this chapter.  
Each potential Sus inhibitor was initially assayed at a concentration of 100 μM against 
both B. thetaiotaomicron (Bt) and B. fragilis (Bf). These species are both prominent 
members of the human gut microbiome (GM) and their carbohydrate utilization has been 
well documented as described in the first chapter. Bt also possess the most well 
characterized Sus system. These characteristics make Bt and Bf ideal candidates for initial 
screening. While there are more clinically relevant species, such as Bacteroides dorei and 
Bacteroides vulgatus, their difficulty to culture and less-characterized starch utilization 















dorei where conducted later with compounds that displayed inhibitory properties and are 
described in a following chapter. 
To assess the impact of the glucosidase inhibitors on Sus, growth was investigated in a 
variety of glucose-based carbohydrates, such as the monosaccharide glucose, its 
disaccharide maltose, and the complex starches pullulan and potato starch. Pullulan (II-9) 
is an isolate from the fungus Aureobasidium pullulans and consists of a trisaccharide of a-
1,4-linked glucose, with each trisaccharide unit connected by a a-1,6-linkage. While not 
commonly found in the human diet, it is used to make edible films such as those found in 
several oral hygiene products such as Listerine® PocketPaks® breath strips. There are also 
several pullulanases, enzymes specific for the degradation of pullulan, incorporated into 
Sus. Potato starch (II-10), on the other hand, is commonly found in the human diet and 
consists of a 20:80 mixture of amylose and amylopectin. Amylose is a glucose polymer 
consisting exclusively of a-1,4-linkages, while amylopectin consists primarily of the same 
a-1,4-bonds, but also occasionally includes an a-1,6-linkage that serve as branching points
for the polymer. If the human amylase inhibitors II-1 through II-6 are capable of arresting 
the activity of Sus, the following should be observed: since Sus is required to degrade and 
import starches as a metabolite, growth in their presence should be noticeably diminished. 
Additionally, growth in the presence of glucose should not be impacted since Sus is not 
engaged for the metabolism of monosaccharides. Robust growth in glucose would also 
demonstrate that the compounds exhibit no inherent microbicidal properties. Maltose 
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serves as a transcriptional regulator for the Sus, but may be small enough to bypass certain 
Sus components, so a growth response in its presence  was difficult to predict.  
In initial studies, we also sought to investigate non-starch based polysaccharides to 
determine if any inhibition would be observed with carbohydrates that are not degraded by 
the Sus. To this end, growth in chondroitin sulfate, a host derived glycan composed of 
alternating units of glucuronic acid and N-acetylgalactosamine, was also probed. The 
potential for inhibition of non-starch based polysaccharides by Sus inhibitors is further 
discussed in Section 2.3. 
 
Figure 2.4: Carbohydrates initially assayed: Monosaccharide glucose (II-7), disaccharide 
maltose (II-8), starch based polysaccharides pullulan (II-9) and potato starch (II-10), and 



















(R = H, Amylose 20%) 
















































 Growth inhibition was assessed by comparing growth curves of treated (i.e. 100 µM 
concentration of target drugs) and non-treated cultures grown in an incubating 96-well 
plate reader housed in an anaerobic chamber.  While slightly higher than what is typically 
used for a clinically relevant therapy, this concentration allowed us to quickly screen for 
active compounds for further study at lower concentrations. Cultures were initially 
generated from frozen stocks that were streaked out on tryptone, yeast extract and glucose 
(TYG) agar plates and incubated at 37°C under anaerobic conditions for 48 to 72 h. A 
single colony was taken from the agar plate and used to inoculate 10 mL of fresh TYG 
broth which was then incubated anaerobically for 18 h at 37°C. TYG is a rich medium that 
allows for growth of dense, healthy cultures prior to introducing them to the more stressful 
conditions of nutrient-limited media. Since TYG is chemically undefined and may contain 
unwanted polysaccharides, we next transferred 100 µL of the TYG culture to 10 mL of a 
chemically defined Bacteroides minimal media containing the polysaccharide or 
monosaccharide of interest as the only available carbon source. This minimal media 
excludes any components commonly found in bacterial medium that could contain 
unwanted carbohydrates sources, such as tryptone or yeast extract, allowing for control 
over what carbohydrates are available. After another 18 h anaerobic incubation period, 
minimal media cultures where then used to carry out anaerobic 96-well plate assays with 
each carbohydrate source and potential inhibitor in fresh minimal media. The 96-well 
plates were incubated for 48 hours at 37°C inside of a BioTek 96 well plate reader. Culture 
growth was measured by optical density readings at 600 nm (OD600) taken every 30 m with 
a 15 s shake prior to each reading. Inhibition was evaluated by noting the time point at 
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which the maximum OD600 was achieved in an untreated culture and dividing the OD600 of 
the treated culture at the same time point by this value. All assays were conducted in at 
least duplicate on a single day, with each assay repeated on three separate days to ensure 
reproducibility. Select representative growth curves are shown throughout the chapter. 
Once a potential Sus inhibitor was identified, a dose response assay was performed to 
identify the lowest effective dose. 
2.2 Initial Screens of Potential Sus Inhibitors 
 Both quercetin and rutin proved to be insoluble in water. Even when pre-dissolved in 
ethanol or DMSO, both compounds precipitated upon addition to media. Because of this, 
the flavonoids were set aside until they could be modified synthetically to increase their 
solubility (See chapter 5). Neither miglitol, voglibose, or CS-1036 showed any inhibitory 
properties when assayed at 100 µM (Figures 2.A1 through 2.A6). Bf was not capable of 
growth in chondroitin sulfate, though Bt was and again was unaffected by miglitol, 
voglibose, and CS-1036 at a concentration of 100 µM (Figures 2.A3 and 2.A6).  
 Out of all of the compounds in our initial screens, only acarbose demonstrated growth 
inhibition in the presence of starch-based polysaccharides over the course of 48 h. As 
hypothesized, no inhibition was seen when the organisms were grown in glucose minimal 
medium, indicating that acarbose has no inherent ability to impact cell growth in any 
manner when Sus is not engaged by the presence of complex carbohydrate (Figure 2.5). 
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Upon being introduced to the starch based polysaccharides, pullulan and potato starch, Bt 
treated with 100 μM acarbose only grew to 4.3 ± 0.4% and 0.9 ± 0.6% of the untreated 
culture, respectively.  Similarly,  Bf only grew to 3.7 ± 0.3 % and 0.4 ± 0.3% compared to 
the untreated cultures. This correlates to over 90% growth inhibition in each of the 
polysaccharides for both species and inhibition was consistent once stationary phase was 
achieved over the course of the 48 h assay. When grown in maltose minimal medium, 
acarbose displayed a different response. With Bt both the lag phase and doubling time of 
the exponential phase were increased, although the acarbose-treated culture was able to 
achieve a similar culture density by the end of the assay. For Bf, there was a slight decrease 
in growth observed in the minimal media supplemented with maltose, but not to the same 
degree as seen with minimal media supplemented with the various starches (Figure 2.6). 
In chondroitin sulfate there was a small delay in lag time, but unlike what was seen with 
the starches, the doubling time and max OD600 achieved where consistent with the 
untreated cultures (Figure 2.7) making the compound a less than ideal inhibitor when 
compared to the results observed in the starches. The selective inhibition of growth in 
minimal media containing the starch-based polysaccharides with a lack of inhibition by the 
drug in glucose minimal medium (Table 2.1) demonstrates that acarbose treatment 
effectively arrests the Sus, thus depriving the cells of their primary energy source and 
interrupting their growth.  
 While unhindered growth in glucose minimal medium as shown in Table 2.1 provides 
evidence that treatment with acarbose was non-microbicidal, a cell count assay with both 
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Bt and Bf cultures grown in glucose, pullulan, and potato starch minimal media with and 
without 100 μM acarbose was also conducted to ensure that treated cultures still contained 
viable cells. Viable cells where assessed in the form of colony forming units (CFUs) 
counted from TYG agar plates. As expected cultures grown in glucose minimal medium 
with and without acarbose provided the same number of CFUs, once again demonstrating 
that acarbose treatment is non-lethal. Additionally, the CFU counts obtained from cultures 
grown in potato starch and pullulan minimal media matches the inhibition seen in the 
growth curves (Figure 2.8). 
Figure 2.5: Growth curves demonstrating the differing impact of acarbose treatment on 
the growth of Bt and Bf in minimal media containing the monosaccharide glucose vs. 






the presence (dashed blue) or absence (black) of 100 µM acarbose in minimal media 
containing glucose. B) Growth of Bf in the presence (dashed blue) or absence (black) of 
100 µM acarbose in minimal media containing glucose C) Growth of Bt in the presence 
(dashed blue) or absence (black) of 100 µM acarbose in minimal media containing 
pullulan. D) Growth of Bf in the presence (dashed blue) or absence (black) of 100 µM 
acarbose in minimal media containing pullulan.  
Figure 2.6 Growth of Bt (A) and Bf (B) in minimal media containing maltose in either the 
presence (dashed blue) or absence (black) of 100 µM acarbose. While some effects of 
growth can be observed with Bt, it is not to the same extent as with the starches, and over 























 Figure 2.7 Growth of Bt in minimal media supplemented with chondroitin sulfate with 
(blue dashed) and without (black) 100 µM acarbose. 
Table 2.1: Percent growth of bacterial cultures in various carbohydrate sources challenged 
with 100 μM acarbose. Growth in the presence of minimal media containing glucose shows 
no impact on growth. Inhibition is only obtained when in the presence of starches.  
Carbohydrate Bt (% Growth) Bf (% Growth) 
Glucose  89.4 ± 6.6 94.3 ± 4.7 
Maltose  3.7 ± 3.9 46.5 ± 23.9 
Pullulan  4.3 ± 0.4 3.7 ± 0.3 











Figure 2.8: Percent growth after 18 h calculated by CFUs of cultures treated with 100 µM 
Acarbose. Inhibition matches with that seen in the minimal media assays conducted in the 
96-well plate reader.
 With this established, a series of dose-response assays (Figure 2.9) were conducted in 
order to ascertain the minimum concentration of acarbose needed to reproduce the 
observed 90% inhibition and to calculate the IC50 of acarbose treatment. Both Bt and Bf 
were grown in minimal medium containing either pullulan or potato starch with acarbose 
at a concentration of 0.1, 0.5, 1, 5, 10, 50, and 100 μM. For Bt in both pullulan and potato 
starch, growth was not markedly impacted at concentrations ranging from from 0.1 to 1 
μM. At 5 and 10 μM concentrations of acarbose, growth was noticeably diminished. 
Concentrations above 10 μM showed the 90% growth inhibition seen previously. Bf in 
pullulan demonstrated a similar inhibition profile to Bt, but in potato starch, growth was 





Figure 2.9: Acarbose dose response assays of Bt and Bf grown in the presence of minimal 
media containing either pullulan or potato starch. A) Dose response of Bt in the presence 
of pullulan and 0.1 – 100 μM acarbose. B) Dose response of Bf in the presence of pullulan 
and 0.1 – 100 μM acarbose. C) Dose response of Bt in the presence of potato starch and 





























































































































































100 μM acarbose. Plots of growth data and the resulting line equation used to generate IC50 
for each associated growth curve can be found in Appendix II Figure 2.A8. 
2.3 Investigating the effects of Acarbose on the Fructan Sus-like system 
 While the starch degrading suite of enzymes that comprise the Sus were the primary 
target of these studies, there was a concern that acarbose may be able to inhibit a similar 
set of proteins comprising Sus-like systems responsible for the degradation of non-starch 
based polysaccharides in these species. In order to forage for carbohydrates in the absence 
of glucose, maltose, or starches, Bacteroides employ a variety of these Sus-like suites 
encoded in gene clusters called polysaccharide utilization loci (PULs) that are capable of 
degrading a range of non-starch based carbohydrates. Each Bacteroides species can contain 
a multitude of these PULs8, for example Bt possess 88 different PULs, each specific for 
different classes of polysaccharides, and are upregulated in their presence.9, 10 These Sus-
like enzyme clusters incorporate an analogue of Sus C and Sus D, and other proteins similar 
to those found in the canonical Sus of Bt may also be present. As an example, the Sus-like 
system of Bt responsible for the degradation of fructans (i.e. fructose-based 
polysaccharides) compared to the canonical Bt Sus can be seen in Figure 2.10.11 Both the 
inner and outer membrane protein composition of fructan Sus-like system  mirrors that of 
the canonical Sus with initial recognition and glycolysis related proteins on the outer 
membrane with transport proteins to shuttle initial degradation products through the cell 
membrane. Glycosides in the periplasm are also present to further degrade oligomers that 
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are then transported through the inner cell wall where they can then be used for the various 
metabolic process of the cell. Additionally both Sus and the Fructan Sus-like suite (FSL) 
contain a TonB receptor and regulatory proteins that upregulate production of the protein 
complex in the presence of the target polysaccharide.  
 Figure 2.10: Comparison of the protein components found on both the inner and outer 
cell walls of Bt that comprise Sus, and the fructan Sus-like system. Of note is the 
remarkable similarity between the protein complexes in both components and assembly. 
 Due to the similarity in composition of the Sus and the fructan Sus-like suite, there was 
a concern that acarbose may show some inhibitory properties against other Sus-like 
enzyme suites,  resulting in the disruption of other Sus-like gene clusters expressed by these 
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organisms. As discussed previously, it has already been demonstrated that the Sus-like 
system for chondroitin sulfate was unaffected by treatment with 100 µM acarbose. In order 
to further probe the likelihood of cross reactivity among PUL encoded systems, we 
performed similar assays targeted at the fructan Sus-like enzyme suite. In addition to being 
a second Sus-like suite to assay against, this system has been characterized in Bt and 
demonstrates the remarkable amount of similarity that can be found between the canonical 
Sus and Sus-like suites. Like with chondroitin sulfate, if acarbose is exclusively targeting 
the starch pathway, no growth inhibition should be seen in the presence of fructans. On the 
other hand, if acarbose is a more general inhibitor of polysaccharide utilization in 
Bacteroides, a disruption in growth would be observed. Bt and Bf where challenged with 
acarbose in the presence of the monosaccharide fructose, the disaccharide sucrose (i.e. 
composed of a glucose and fructose unit), and the fructans, inulin and levan, in minimal 
media. Structures for these carbohydrates, as well as the observed percent growth in the 
presence of acarbose can be seen below in Table 2.2 
 As with glucose, fructose utilization bypasses the FSL and is utilized by the cell in both 
the presence and absence of  acarbose. One aspect of note is that Bt preferentially grows in 
levan and shows no inhibition of growth when treated with acarbose. Bf prefers inulin and 
there was a slight inhibition in growth in the presence of acarbose, 69.4 ± 22.6%. While 
this indicates that there may be a slight inhibitory affect, it is not as debilitating as what is 
seen upon acarbose treatment in minimal media containing starches.  
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Table 2.2: Percent growth of Bt and Bf in fructose, sucrose, and the representative fructans 
inulin and levan when challenged with 100 µM acarbose. Unlike with the starch based 
polysaccharides, growth in the fructans is unaffected, demonstrating that acarbose thus far 
specifically shuts down Sus while having a limited effect on Sus-like enzyme suites. 
2.4 Ruminococcus bromii and Lactobacillus reuteri: Examples from the Firmicutes 
Phylum 
Since each phylum present in the HGM plays a different role in the health of their host, 
any potential treatment targeting its constituents should be as specific as possible, ideally 
only disrupting the growth of a single phylum, or if possible a single genus. While members 
of the Bacteroidetes phylum make up a large portion of the human GM, they are not the 
primary constituent found in the gut. This distinction belongs to the Firmicutes, which can 
represent up to 40% of the microbiota in western adult populations.12,13  Thus, we next 
wanted to ascertain what effects acarbose treatment would have on the growth of select 
Carbohydrate Structure Bt (% Growth) Bf (% Growth)
Fructose 90.8 ± 5.7 81.4 ± 6.4
Sucrose 78.9 ± 7.6 97.5 ± 3.2
Levan 94.4 ±1.6 N/A


















































members of the Firmicutes phylum, and ideally observe little to no growth inhibition when 
exposed to acarbose.  
Thus, two representative organisms were chosen. The first was Ruminococcus bromii, 
which similar to the Bacteroides spp., primarily relies on polysaccharide metabolism as a 
main source of energy.  This organism is also capable of metabolizing starches, albeit using 
different enzymatic machinery. While both Bacteroides and Ruminococcus can process 
similar complex carbohydrates, the systems employed are vastly different. Unlike the 
membrane bound Sus, R. bromii  employs a more modular approach by secreting protein 
complexes composed of carbohydrate binding proteins and amylases as well as proteins 
called scaffoldins that can bind other scaffoldins or dockerins located on R. bromii’s cell 
wall.14 Once these secreted enzyme complexes locate and bind with free carbohydrates, 
they can then be retrieved by the cell and further degradation or carbohydrate capture can 
occur. Additionally Lactobacillus reuteri was chosen to see what effects, if any, acarbose 
treatment would have on a probiotic Firmicute that preferentially utilizes mono- and 
oligosaccharides instead of polysaccharides.15 
These experiments allowed us to establish several things regarding the selectivity of 
acarbose to inhibit growth the HGM constituents. If inhibition was seen with R. bromii, it 
would suggest that acarbose could potentially inhibit any microbe from any phyla that 
relies on the degradation of polysaccharides as an energy source instead of those 
specifically belonging to members of the Bacteroidetes. If inhibition is seen in L. reuteri it 
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would suggest that acarbose inhibition may affect more than just polysaccharide usage. 
Since our hypothesis of selective HGM modulation relies on acarbose specifically 
disrupting the growth of the Bacteroidetes phylum, inhibition of either Firmicute would 
not be ideal.  
Due to their differing growth requirements, both the medium used and the assay had to 
be altered for the Firmicutes. R. bromii is a strict anaerobe, so all media was left inside of 
an anaerobic chamber for at least 12 h prior to use to allow for residual oxygen to diffuse 
out. Additionally, all procedures were carried out inside of an anaerobic chamber. 
Conditions for growing R. bromii on agar have yet to be established, so frozen stocks where 
used to directly inoculate 10 mL of Ruminococcus (RUM) media. Liquid cultures where 
then incubated at 37°C for 48 h. No defined minimal medium is available for R. bromii, so 
RUM was used to carry out assays inside of the 96-well plate. Assays where conducted for 
72 h since it takes longer for R. bromii to exit the lag phase and enter their exponential 
growth phase. Cultures with no added carbohydrates source were conducted alongside the 
assays to ensure no unwanted growth was observed due to RUM containing unwanted 
polysaccharides. 
For L. reuteri assays, the frozen stock was streaked out initially on De Man, Rogosa, 
and Sharpe (MRS) agar plate and inoculated anaerobically for 48 hrs. A single culture from 
the agar plate was then used to inoculate 10 mL of MRS broth which was then sealed with 
rubber stoppers followed by an aluminum crimp cap. Like R. bromii, no reported minimal 
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media is available for L. reuteri. Instead it was decided to use MRS broth as a semi-defined 
medium. Cultures with no added carbohydrate source were again conducted alongside 
those with glucose to ensure no unwanted growth was observed. The 96-well plate assays 
were conducted in the same manner as described earlier for the Bacteroides.  
 At 100 μM acarbose, L. reuteri showed no evidence of growth inhibition in either 
glucose, or its disaccharide maltose. For R. bromii fructose was chosen as the 
monosaccharide for the assay because the organism is not capable of metabolizing glucose. 
R. bromii growth was unaffected in fructose minimal media in the presence of 100 μM
acarbose , though a slight growth alteration can be seen with the polysaccharides, pullulan 
and potato starch. Fortunately, the effect is greatly diminished when compared to that 
observed for the Bacteroides spp. A decrease in doubling time was observed in minimal 
media containing pullulan meaning the bacteria where taking longer to divide, although the 
cultures achieved a similar level of growth as compared to the untreated culture by the end 
of the assay. In maltose, growth was moderately affected, with cultures only growing to 
53.8 % of the untreated culture. While these data indicate that the starch capturing and 
degrading mechanisms present in R. bromii are somewhat affected by acarbose (Figure 
2.11), it is nowhere near as disruptive as on the Bacteroides Sus described earlier, where a 
roughly 90% inhibition was observed that was consistent throughout the period monitored. 
The experiments described above showed that treatment with acarbose at 100 μM can 
selectively inhibit the growth of representative Bacteroides species in minimal media 
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containing starch-based polysaccharides.  We next wondered whether any of the 
compounds that had not exhibited any inhibitory properties in the context of the 
Bacteroides Sus, would instead demonstrate the capacity to inhibit starch utilization of R.  
bromii. If so, this would give us a set of compounds that could selectively inhibit either the 
Bacteroidetes or Firmicute starch utilization. Recent literature has demonstrated that this is 
a possibility, showing that both miglitol and voglibose can inhibit the isolated starch 
degrading enzymes of certain Ruminococcus spp. Unfortunately neither voglibose or 
miglitol demonstrated inhibitory activity of R. bromii at a concentration of 100 μM in the 
presence of either pullulan or potato starch (Figure 2.A7).  
Figure 2.11 Growth curves of R. bromii in a variety of polysaccharides challenged with 
100µM acarbose. A) Growth of R. bromii in RUM supplemented with fructose in the 
presence (blue dashed) or absence (black) of 100µM acarbose. B) Growth of R. bromii in 
RUM supplemented with maltose in the presence (blue dashed) or absence (black) of 













































presence (blue dashed) or absence (black) of 100µM acarbose. D) Growth of R. bromii in 
RUM supplemented with potato starch in the presence (blue dashed) or absence (black) of 
100µM acarbose. 
2.5 Escherichia coli: A common commensal gut microbe 
 It was also decided to investigate the impact of acarbose on the growth of Escherichia 
coli, another common gut microbe belonging to the Proteobacteria phylum. While this 
organism makes up less than 1% of the population of the GM, it is found in a majority of 
GMs and helps to prevent the establishment of pathogenic organisms in the environment. 
Additionally, this organism colonizes the gut at birth and plays an essential in the training 
of the innate immune system. Together these factors highlight the beneficial roles this 
organism plays with the host, and therefore it was essential to establish if acarbose had any 
deleterious effects on its ability to thrive. 
 Frozen E. coli stocks were initially streaked out on tryptic soy agar (TSA) and 
incubated aerobically for 18 h at 37 °C. A single culture was then used to inoculate 10 mL 
of tryptic soy broth (TSB) which was again incubated aerobically for 18 h at 37 °C. For the 
growth assay, 25 uL of the liquid overnight culture was used to inoculate 20 mL of M9 
broth, a minimal media formulated for growth of E. coli, supplemented with either glucose 
or pullulan. Prior to inoculation, acarbose at a concentration of 100 µM was added if 
necessary. These cultures were then incubated in a water bath at 37 °C. Aliquots were taken 
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every hour for 8 h and used to measure the OD600. Cultures where then allowed to incubate 
until 24 h, at which point a final OD600 measurement was taken. 
 As seen in Figure 2.12, growth of E. coli was unaffected by acarbose at a 
concentrations of 100 µM in both the monosaccharide glucose, as well as with the complex 
carbohydrate pullulan, with the treated cultures growing in the same manner as the 
untreated ones. This suggests that acarbose is unable to interfere with E. coli growth, again 
highlighting the specificity of acarbose toward both the Bacteroides genus, as well as the 
Sus system. 
Figure 2.12 Growth curves of E. coli grown in the presence (dashed blue) or absence 
(black) of 100 µM acarbose. A) Growth in M9 media supplemented with glucose. B) 





















2.6 Effects of Acarviosin, a truncated analogue of acarbose, on Sus 
 As it has been established thus far, acarbose only shows dramatic inhibition with 
Bacteroides spp. in the presence of starch-based carbohydrates indicating a disruption of 
the Sus. Even when the structurally similar fructan Sus-like system is challenged with 
acarbose, no inhibition is observed. An interesting structural observation noted was that 
acarbose contains a maltose unit, the disaccharide of glucose and a structural unit of starch. 
This molecule only interrupts starch degradation. It was hypothesized that this maltose unit 
may play a role in the observed selective disruption of the Sus. Additionally, X-ray crystal 
structures have been obtained with acarviosin bound to Sus G.3  

































 In order to test this assumption, and probe for evidence of an inhibitory mechanism, we 
challenged the representative Bacteroides species with acarviosin, a truncated analogue of 
acarbose that lacks the maltose unit (Figure 2.13). If this portion of acarbose is necessary 
for the observed inhibition, then when challenged with acarviosin in the presence of 
pullulan or potato starch one of two things should be observed: 1) No growth inhibition 
indicating that acarviosin has lost its ability to disrupt this system without the presence of 
glucose. 2) Diminished growth inhibition compared to acarbose indicating that acarviosin 
possesses inherent, though limited inhibitory properties. Either outcome would be of 
interest since it would suggest that inhibition may be reliant upon the incorporations of the 
carbohydrate specific for the targeted system. In other words, the glucose moiety possessed 
by acarbose is what allows for the its ability to inhibit Sus. Additionally it may also explain 
the lack of inhibition seen in the fructan Sus-like system suggesting that inhibition is tied 
to the inhibitor possessing a unit matching the polysaccharide being digested (i.e. glucose 
residues are needed to stop starch digestion, so fructose would be needed to stop fructan 
digestion, xylose to stop xylan digestion, etc.). This information could be leveraged to 
make analogues of acarbose or other inhibitors where glucose is exchanged for a different 
monosaccharide in order to target the Sus-like suite responsible for the degradation of its 
corresponding polymer. 
 Inhibitory effects of acarviosin were interrogated in the same manner as with acarbose. 
Both Bt and Bf where assayed in minimal media containing glucose as well as the starches, 
pullulan and potato starch, with either 100 μM acarviosin or 100 μM acarbose. Growth 
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curves in Figure 2.14 show overlays of the treated and untreated cultures and two differing 
responses can be observed. In potato starch, both acarbose and acarviosin demonstrate the 
same high level of inhibition seen previously.  Conversely,  in minimal medium containing 
pullulan, acarviosin no longer exhibits inhibitory properties. Without the glucose units, 
acarviosin only partially retains its inhibitory properties in pullulan, with a diminished 
inhibitory capacity in Bt, and absence of inhibition with Bf. These findings where further 
supported with dose response assays conducted with Bt and Bf grown in minimal media 
supplemented with potato starch. These assays revealed IC50 values of 12.2 μM and 9.7 μM  
for Bt and Bf respectively. These values are higher than those found with acarbose (Figure 
2.15), again demonstrating that the loss of the glucose units seems to hinder acarbose’s 
inhibitory properties against Sus. Of note is that while both potato starch and pullulan are 
composed entirely of glucose, they differ in their arrangement with pullulan including more 
a-1,6 glycosidic bonds as opposed to potato starch which has mainly a-1,4 glycosidic
bonds. This difference may play a role in the selective inhibition observed with acarviosin. 
Regardless, it is possible to manipulate the efficacy of acarbose through changes to its 
molecular structure, in this case the loss of its glucose units. Because of this, other changes 
such as adding or subtracting glucose units to potentially increase the inhibitory response 
or replacement of glucose with other carbohydrates in order to target a variety of PULs has 
been proposed and offer a deep vein of experiments to mine. Further studies looking into 
acarviosin’s effects on such Sus-likes, like those that govern fructan or xylan utilization, 
would help establish the selectivity of acarviosin’s effects, and if inhibition is seen further 
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studies in to modifications of acarviosin with different classes of carbohydrates would be 
warranted. 
Figure 2.14 Growth curves of Bt and Bf challenged with either 100 µM acarbose or 100 
µM acarviosin in a variety of carbohydrate sources. A) Bt in minimal media supplemented 
with glucose in the presence of 100 µM acarbose (blue dashed), 100 µM acarviosin (orange 
dashed), or with no added amylase inhibitor (black). B) Bf in minimal media supplemented 





































































dashed), or with no added amylase inhibitor (black). C) Bt in minimal media supplemented 
with pullulan in the presence of 100 µM acarbose (blue dashed), 100 µM acarviosin 
(orange dashed), or with no added amylase inhibitor (black). D) Bf in minimal media 
supplemented with pullulan in the presence of 100 µM acarbose (blue dashed), 100 µM 
acarviosin (orange dashed), or with no added amylase inhibitor (black). E) Bt in minimal 
media supplemented with potato starch in the presence of 100 µM acarbose (blue dashed), 
100 µM acarviosin (orange dashed), or with no added amylase inhibitor (black). F) Bf in 
minimal media supplemented with potato starch in the presence of 100 µM acarbose (blue 
dashed), 100 µM acarviosin (orange dashed), or with no added amylase inhibitor (black). 
 
Figure 2.15 Acarbose dose response assays of Bf and Bt grown in the presence of minimal 
media containing either pullulan or potato starch. A) Dose response of Bt in the presence 
of potato starch and 0.1 – 100 μM acarbose. B) Dose response of Bf  in the presence of 































IC50: 12.2 μM 
IC50: 9.7 μM 
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equation used to generate IC50 for each associated growth curve can be found in Appendix 
II Figure 2.A9. 
2.7 Conclusions 
Throughout this chapter several characteristics of the Bacteroides Sus and Sus-like 
systems were elucidated through the use the small molecule inhibitor acarbose. 
Importantly, our underlying hypothesis was confirmed: through the use of a small molecule 
inhibitor, we could disrupt the Sus of various Bacteroides species in order to inhibit growth 
in a non-lethal manner with concentrations as low as 1 μM acarbose demonstrating a nearly 
90% growth inhibition. This method, as of our current understanding, is specific for starch 
utilization while not affecting any similar Sus-like enzyme suites present for metabolizing  
chondroitin sulfate or fructans. Finally treatment of a few members of the Firmicutes 
phylum with acarbose has no effect on the mono- and oligosaccharide user L. reuteri, and 
a limited effect on polysaccharide user R. bromii, showing that this pronounced growth 
inhibition is limited to members of the Bacteroides genus. 
While investigating acarbose’s effects on Bacteroides growth, several instances where 
Sus and Sus-like systems were not as uniform between species as previously expected were 
uncovered. For instance Bt and Bf both showed different preferences for specific fructans 
and potato starch components, though these differences do not impact the ability of 
acarbose to inhibit Sus. As discussed in the opening of this chapter, Bt and Bf were ideal 
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candidates for initial assays due to their relative ease of culturing. To assess if the same 
impact can be seen in a more clinically relevant species, the following chapter will 
highlight the impact of acarbose on several strains of the clinically relevant microbe, 
Bacteroides dorei, as well as discuss the experimental adaptations necessary to overcome 





Bacteroides minimal media was prepared following the procedure described by 
Martens, et al.9, with the exception of the carbon source being added just prior to bringing 
to final volume. TYG agar and broth where prepared following the procedure described in 
the Anaerobe Laboratory Manual.16 Ruminococcus bromii was grown in RUM media, 
which was prepared following the procedure described by Flint et al.14 Lactobacillus 
reuteri was grown in modified MRS media that was prepared as described in the DifcoTM
and BBLTM Manual17 and supplemented with the appropriate carbohydrate source prior to 
being brought to final volume. Escherichia coli was grown in modified M9 Medium. M9 
medium was prepared following the protocol described in the Difco™ and BBL™ 
Manual17 and supplemented with the appropriate carbohydrate source prior to being 
brought to final volume.  
96 Well Plate Growth Assays For Bt and Bf 
Growth on TYG Agar 
 Frozen bacterial stock were struck out on Tryptone, yeast, and glucose (TYG) agar 
plates using sterile 1 μL inoculating loops. Agar plates were then stored in BBL Anaerobic 
Jars with a BD Gas-Pack EZ anaerobe system and incubated at 37 ° C for 48 – 72 h.  
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TYG Broth Overnight Culture 
 After incubation, a single colony from the TYG plate was transferred to a sterile culture 
tube with 10 mL of sterile TYG broth with 100 μL of a 100X (L)-cysteine solution (50 
mg/mL (L)-cysteine in 10 mM aq. HCl). A sterile cotton ball was placed partially into the 
opening of the tube, leaving about half of the cotton ball out of the tube. The exposed part 
of the cotton ball was ignited using a match, and once the flame had extinguished itself, 
the cotton ball was pushed roughly an inch into the tube.  To the top of the cottonball,  a 
200 μL of aliquot of a 35 % w/v pyrogallol solution and 200 μL of saturated aq. sodium 
bicarbonate solution were pipetted. Culture tubes were then capped with a rubber stopper 
followed by an aluminum crimp cap and incubated at 37° C overnight.  
Minimal Media with Glucose Overnight Culture 
 The following day, 100 μL of the TYG liquid broth culture was transferred to a sterile 
culture tube containing 10 mL of sterile minimal media supplemented with glucose. To the 
media, 100 μL of a 100X (L)-cysteine (50 mg/mL (L)-cysteine in 10 mM aq. HCl) was 
added. A sterile cotton ball was placed partially into the opening of the tube, leaving about 
half of the cotton ball out of the tube. The exposed part of the cotton ball was ignited, and 
once the flame had extinguished itself, the cotton ball was pushed roughly an inch into the 
tube. After, 200 μL of 35 % w/v pyrogallol solution and 200 μL of saturated aq. sodium 
bicarbonate were pipetted on top of the cotton ball. Cultures were then capped with a rubber 
stopper followed by an aluminum crimp cap and incubated at 37° C overnight.  
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Plate Assays 
 The following day in an anaerobic chamber, 500 μL of the minimal media liquid culture 
was centrifuged into a pellet for roughly 1 min and the supernatant was removed. The pellet 
was the resuspended in 500 μL of 2x MM with no carbohydrate source and used to 
inoculate 25 mL of 2X MM with no carbohydrate source. 100 μL of the 2X carbohydrate 
source was aliquoted into a well of a 96 well plate, followed by 100 μL of the inoculated 
2X MM. If an inhibitor was being tested, it was present in the 2X carbohydrate source, also 
at a 2X concentration. Plates where then inserted into a BioTek Epoch 2 Microplate 
Spectrophotometer where they were incubated at 37 oC for 48 h with a 2 °C gradient. 
During incubation, the optical density (OD) at 600 nm was measured every half hour. Prior 
to each measurement, there was a 15 s shake. The resulting data where transferred to 
Microsoft Excel, and used to generate growth curves  in the presence and absence of the 
inhibitor. Assays were conducted in at least duplicate on a single day, with each assay 
repeated on three separate days to ensure reproducibility. 
96 Well Plate Growth Assays For L. reuteri 
Growth on MRS agar 
Frozen bacterial stocks were struck out on MRS agar plates using sterile 1 μL inoculating 
loops. Agar plates were then stored in BBL Anaerobic Jars with a BD Gas-Pack EZ 
anaerobe system and incubated at 37 ° C for 48 h.  
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MRS Broth Overnight Culture 
 After incubation, a single colony from the MRS plate was transferred to a sterile culture 
tube with 10 mL of sterile MRS broth. Cultures were then capped with a rubber stopper 
followed by an aluminum crimp cap and incubated at 37 °C overnight.  
Plate Assays 
 The following day in an anaerobic chamber, 500 μL of the MRS liquid culture was 
centrifuged into a pellet for roughly 1 min and the supernatant was removed. The pellet 
was then resuspended in 500 μL of 2x MRS with no carbohydrate source and used to 
inoculate 25 mL of 2X MRS with no carbohydrate source. 100 μL of the 2X carbohydrate 
source was aliquoted into a well of a 96 well plate, followed by 100 μL of the inoculated 
2X MM. If an inhibitor was being tested, it was present in the 2X carbohydrate source, also 
at a 2X concentration. Plates where then inserted into a BioTek Epoch 2 Microplate 
Spectrophotometer where they were incubated at 37 oC for 48 h with a 2 °C gradient. 
During incubation, the optical density (OD) at 600 nm was measured every half hour. Prior 
to each measurement, there was a 15 sec shake. The resulting data where transferred to 
Microsoft Excel, and used to generate growth curves in the presence and absence of the 
inhibitor. Assays were conducted in at least duplicate on a single day, with each assay 
repeated on three separate days to ensure reproducibility. 
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96 Well Plate Growth Assays For R. bromii 
RUM Broth liquid Culture 
 RUM broth was left inside of an anaerobic chamber with the lid loosened in order for 
oxygen to diffuse out of the medium. After 24 h, inside of the anaerobic chamber, frozen 
bacterial stocks were used to inoculate 10 mL of sterile RUM broth supplemented with 
fructose using a sterile 1 μL inoculating loop in sterile culture tubes. Tubes were sealed 
with rubber stoppers and an aluminum crimp cap prior to removing from the anaerobic 
chamber. Liquid cultures were then incubated at 37 oC for 72 h. 
Plate Assays 
 The day prior to the assay, 2X RUM with no carbohydrate source and 2X carbohydrates 
sources with and without inhibitors were placed in the anaerobic chamber with lids 
loosened in order for oxygen to diffuse out of the media. In an anaerobic chamber, 500 μL 
of the RUM liquid culture was centrifuged into a pellet for roughly 1 min and the 
supernatant was removed. The pellet was the resuspended in 500 μL of 2x RUM with no 
carbohydrate source and used to inoculate 25 mL of 2X RUM with no carbohydrate source. 
100 μL of the 2X carbohydrate source was aliquoted into a well of a 96 well plate, followed 
by 100 μL of the inoculated 2X RUM. If an inhibitor was being tested, it was present in 
the 2X carbohydrate source also at a 2X concentration. Plates where then inserted into a 
BioTek Epoch 2 Microplate Spectrophotometer where they were incubated at 37 oC for 48 
h with a 2 °C gradient. During incubation, the optical density (OD) at 600 nm was measured 
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every half hour. Prior to each measurement, there was a 15 sec shake. The resulting data 
where transferred to Microsoft Excel, and used to generate growth curves in the presence 
and absence of the inhibitor. Assays were conducted in at least duplicate on a single day, 
with each assay repeated on three separate days to ensure reproducibility. 
Growth Assays For E. coli 
Escherichia coli Overnight Cultures 
 Overnights were grown from freezer stocks on TSA plates incubated at 37 ˚C for 18 h. 
A single colony was used to inoculate 10 mL of TSB medium and cultures were incubated 
18 h at 37 ˚C.  
Escherichia coli Growth Assay 
  A 25 µL aliquot of the overnight culture was used to inoculate 20 mL of M9 Media 
supplemented with a carbohydrate source. Acarbose was added to the M9 media prior to 
being brought to final volume. Cultures were incubated in a water bath at 37 ˚C. Aliquots 
were taken from cultures every hour for 8 h to measure OD600. A final OD600 measurement 
was taken after 24 h. 
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 Cell Count Assay 
Assay Protocol 
 In an anaerobic chamber, 100 µL of MM with glucose overnight culture was used 
to inoculate 10 mL of minimal media with either glucose, pullulan, or potato starch with 
and without 100 µM acarbose. MM cultures were sealed with a rubber stopper and 
aluminum crimp cap and incubated at 37˚C for 18 h. 100 µL of each culture was then used 
to make 1:10 serial dilutions out to 10-7. 
 Thus, 100 µL of each dilution was spread on TYG plates using sterile cell spreaders, 
and plates were then incubated at 37 ̊ C for at least 48 h in a GasPak™ Anaerobic Jar. After 
incubation, each set of TYG plates were removed from the incubator. Plates containing 
individual colonies numbering between 30 and 300 were included in data analysis. Each 
individual colony represented a single colony forming unit (CFU) from the dilution. Assay 




Figure 2.A1 Growth of Bt in minimal media with (blue dashed) and without (black) 100µM 
miglitol. A) Growth in minimal media containing glucose. B) Growth in minimal media 
containing maltose. C) Growth in minimal media containing pullulan. D) Growth in 



















































Figure 2.A2 Growth of Bt in minimal media with (blue dashed) and without (black) 100µM 
voglibose. A) Growth in minimal media containing glucose. B) Growth in minimal media 
containing maltose. C) Growth in minimal media containing pullulan. D) Growth in 



















































Figure 2.A3 Growth of Bt in minimal media with (blue dashed) and without (black) 100µM 
CS-1036. A) Growth in minimal media containing glucose. B) Growth in minimal media 
containing maltose. C) Growth in minimal media containing pullulan. D) Growth in 



















































Figure 2.A4 Growth of Bf in minimal media with (blue dashed) and without (black) 100µM 
miglitol. A) Growth in minimal media containing glucose. B) Growth in minimal media 
containing maltose. C) Growth in minimal media containing pullulan. D) Growth in 













































Figure 2.A5 Growth of Bf in minimal media with (blue dashed) and without (black) 100µM 
voglibose. A) Growth in minimal media containing glucose. B) Growth in minimal media 
containing maltose. C) Growth in minimal media containing pullulan. D) Growth in 












































Figure2. A6 Growth of Bf in minimal media with (blue dashed) and without (black) 100µM 
CS-1036. A) Growth in minimal media containing glucose. B) Growth in minimal media 
containing maltose. C) Growth in minimal media containing pullulan. D) Growth in 













































Figure 2.A7 Growth of R. bromii  in RUM media with the human amylase inhibitors  
miglitol (red), voglibose (blue dashed) at a concentration of 100µM, or with no inhibitor 
(black). A) Growth in RUM media containing pullulan. B) Growth in RUM  media 


























Figure 2.A8 Dose response assay data and the resulting line equation from Figure 2.9 used 
to calculate the IC50 values. IC50 was determined by solving each equation for x where y = 
50. A) Percent growth of Bt in pullulan with the amylase inhibitor acarbose. B) Percent
growth of Bf in pullulan with the amylase inhibitor acarbose. C) Percent growth Bt in potato 
starch with the amylase inhibitor acarbose. D) Percent growth of Bf in potato starch with 
the amylase inhibitor acarbose. 














































y = -15.17ln(x) + 66.284 
y = -18.33ln(x) + 73.901 y = 23.162x-0.77 
















y = -16.96ln(x) + 72.324 
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Figure 2.A9 Dose response assay data and the resulting line equation from Figure 2.15  
used to calculate the IC50 values. IC50 was determined by solving each equation for x where 
y = 50. A) Percent growth of Bt in potato startch with the amylase inhibitor acarviosin. B) 
Percent growth of Bf in potato starch with the amylase inhibitor acarviosin.  





























y = -19.94ln(x) + 99.939 
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CHAPTER THREE: 
EFFECTS OF ACARBOSE ON FOUR STRAINS OF Bacteroides dorei, A CLINICAL 
ISOLATE 
3.1 Introduction 
 While Bacteroides thetaiotaomicron (Bt) and B. fragilis (Bf) served as valuable proofs 
of concept for continued investigations into acarbose’s use as a therapeutic treatment of 
diseases initiated by gut microbiota dysbiosis, these species are not directly relevant to 
clinical disease. It was decided to search the literature for a more clinically relevant species 
of Bacteroides that has been implicated as a causative agent of a dysbiosis related disease 
state. Once a suitable candidate was identified, treatment with acarbose was again 
evaluated against this new organism in minimal media containing the same glucose-based 
carbohydrates in order to verify that a more clinically relevant species was also susceptible 
to this form of therapy. 
As laid out in the introductory chapter, the initial appeal of investigating the inhibition 
of members belonging to the Bacteroidetes phyla was its direct association with increased 
incidences of type 1 diabetes (T1D). Several investigations have been conducted in order 
to establish the exact genus and/or species predominantly responsible for this shift as a way 
to identify potential causative agents. Specifically, multiple studies have focused on 
tracking changes in the gut microbe population of newborn children genetically 
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predisposed to T1D prior to and after the development of autoimmunity markers in order 
to detect compositional changes that correlate with the appearance of self-reactive 
antibodies. One species that has been linked with such shifts is Bacteroides dorei. For 
instance, a  study focusing on children from Turku, Finland in 20141 followed 76 
genetically at-risk children from birth to two years of age. Over the course of the study a 
total of 22 children went on to exhibit autoimmunity. Stool samples were collected for the 
duration of the study, and using 16S rRNA genomic sequencing, the composition of their 
gut microbiome was tracked and compared over time. As expected, an increase in the 
relative abundance of members belonging to the Bacteroidetes phyla was noticed in 
children that eventually presented with autoimmunity. Specifically the authors identified 
B. dorei as one of the species mainly responsible for this increased abundance.
Additionally, the DIABIMMUNE project has also singled out B. dorei as a primary 
contributor to the observed increase in Bacteroidetes. Similar to the study out of Turku, 
Finland, this study monitored the microbiota of children predisposed to T1D focusing on 
the comparison of subjects from Finland, Estonia, and the Karelia region of Russia.2 While 
these three areas are geographically similar and close together, with Finland bordering 
Karelia, they all have vastly different socioeconomic conditions and incidences of T1D 
inside their respective borders. Specifically, Finland exhibits a six-fold higher incidence of 
T1D compared to the Karelia region.3 Estonia on the other hand has been slowly 
transitioning from T1D rates similar to Karelia to those resembling Finland with this trend 
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coinciding with increasing economic growth.4 Together these three countries serve as a 
spectrum for T1D incidence as it relates to economic development and “westernization”. 
A total of 785 children were included in the study, and stool samples were collected 
from infancy to three years of age. Bacterial 16S rRNA sequencing was again used to track 
changes in the gut microbiota, and identify any relevant changes in populations over time. 
The resulting data showed that children in both Estonia and Finland had an increased 
abundance of Bacteroides as well as increased levels of T1D-associated autoimmune 
markers compared to Karelian children. Specifically of note was that, again, B. dorei was 
a primary contributor to the increase in Bacteroides in the cases where autoimmunity was 
observed.2  
While the exact mechanism behind this association has yet to be elucidated between 
this species and the onset of symptoms, two theories have been put forth that individually 
or together may explain these observations. As discussed in the introduction, a reduction 
in butyrate concentrations brought about by an overabundance of Bacteroides spp. could 
impair the tight junctions of the epithelial lining of the gut and allow for pathogens and 
antigens to cross into the blood stream, thus activating components of the immune system 
that are self-reactive.  
At a species level, lipopolysaccharides (LPS) derived from gut bacteria are necessary 
for the proper training of the innate immune response. Repeated exposure to certain 
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bacterial derived LPS, such as those found in Escherichia coli builds a tolerance to GM 
constituents by the body. Not only does the LPS produced by B. dorei fail to initiate this 
tolerance, but its presence is capable of disrupting E. coli LPS from properly training this 
system in a dose dependent manner. In a further report by the DIABIMMUNE Project, 
children from Russia were shown to primarily be exposed to E. coli LPS, while those from 
Finland and Estonia showed an increase in LPS derived from multiple other bacteria, but 
with a significant contribution from B. dorei. Non-obese diabetic mice treated with E. coli 
derived LPS also displayed a delay in T1D onset compared to mice given LPS from B. 
dorei. 
Taken together, these studies highlight the potential importance of B. dorei as a 
clinically relevant contributor in the development of T1D. Additionally similar increases 
in allergies have been noticed in these studies as well suggesting that elevations in this and 
related populations may play roles in other conditions as well.  For these reason it was 
chosen to be a representative Bacteroides for further investigations with acarbose. The 
primary aim of the investigations described throughout this chapter was to ensure that 
acarbose maintains its inhibitory properties against this species. The Sus system is thought 
to be conserved between species of Bacteroides5, so while the version of Sus belonging to 
B. dorei has yet to be characterized, it was hypothesized that B. dorei would still show
susceptibility to acarbose in the presence of starches. Over the course of the 
DIABIMMUNE study, several strains of B. dorei where isolated, and four of those strains, 
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JR01, JR02, JR03, and JR04, were provided by Professor Eric Triplett (University of 
Florida) for use in the following studies. 
3.2 Use of Acarbose to Inhibit Growth of B. dorei Strains in a Non-Lethal Manner 
Initial investigations focused on repeating the same suite of experiments that were done 
with Bt and Bf with B. dorei using Bacteroides Minimal Media (MM). Unfortunately, poor 
and inconsistent growth was observed in MM supplemented with glucose for all four 
clinical strains of B. dorei. To address this unexpected issue, it was decided to formulate a 
more suitable growth medium. Several media that are commonly used in our lab were 
considered as a basis for the development of a new medium, but ultimately it was decided 
to use a modified version of Ruminococcus (RUM) media.6 Nevertheless, RUM contains 
tryptone and yeast extract, both of which include carbohydrate sources that could interfere 
with the assays by promoting excess growth. To account for this, the amount of both yeast 
extract and tryptone was reduced until little to no growth was observed in cultures 
inoculated with B. dorei without the addition of a supplementary carbohydrates. Reducing 
both tryptone and yeast extract to one fourth of their normal amount fulfilled this criteria 
(Figures 3.1), and no further alterations to the reported formula were necessary. This 
modified Ruminococcus (M-RUM) media was used in place of Bacteroides MM and no 















































Figure 3.1 Growth curves of all four B. dorei strains in M-RUM with no supplemental 
carbohydrate source. A) B. dorei JR01 B) B. dorei JR02 C) B. dorei JR03 D) B. dorei JR04 
 With a working medium established, all four strains of B. dorei were assayed against 
100 μM acarbose in M-RUM supplemented with glucose, maltose, or the polysaccharides, 
pullulan or potato starch. No inhibition was observed with either of the four strains in 
glucose or maltose supplemented M-RUM as can be seen in the growth curves presented 
in Figures 3.2 – 3.3 as well as with the percent growth included in Table 3.1. Conversely, 
growth in both the pullulan and potato starch supplemented M-RUM was again inhibited 
by ca. 90% with all four B. dorei strains in the presence of acarbose (Figure 3.4 – 3.5 and 
Table 3.1). Lack of inhibition in the mono- or disaccharide supplemented M-RUM media 
further highlights that, outside of the context of Sus, acarbose is benign to all species and 
strains of Bacteroides tested thus far. Growth inhibition is only observed in the presence 













































inhibits the Sus, only arresting growth when this system is engaged. These results are 
consistent with the inhibition seen in both Bt and Bf and confirms that this form of treatment 
retains its efficacy on the clinically relevant B. dorei strains. 
Figure 3.2 Growth of B. dorei strains in M-RUM supplemented with glucose in the 
presence (blue) and absence (black) of 100 µM acarbose. A) B. dorei JR01 B) B. dorei 
JR02 C) B. dorei JR03 D) B. dorei JR04. 
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Figure 3.3 Growth of B. dorei strains in M-RUM supplemented with maltose in the 
presence (blue) and absence (black) of 100 µM acarbose. A) B. dorei JR01 B) B. dorei 
JR02 C) B. dorei JR03 D) B. dorei JR04. 
Figure 3.4 Growth of B. dorei strains in M-RUM supplemented with pullulan in the 
presence (blue) and absence (black) of 100 µM acarbose. A) B. dorei JR01 B) B. dorei 
























































































Figure 3.5: Growth of B. dorei strains in M-RUM supplemented with potato starch in the 
presence (blue) and absence (black) of 100 µM acarbose. A) B. dorei JR01 B) B. dorei 
JR02 C) B. dorei JR03 D) B. dorei JR04. 
Table 3.1: Percent growth of the four B. dorei strains challenged with 100 µM acarbose in 












































Carbohydrate JR01 (%) JR02 (%) JR03 (%) JR04 (%)
Glucose 100.7 ± 3.3 100.0 ± 9.9 118.7 ± 23.5 105.8 ± 7.7
Maltose 103.0 ± 11.9 99.4 ± 14.8 123.3 ± 35.6 71.8 ± 11.1
Pullulan 6.5 ± 4.7 10.1 ± 8.5 10.4 ± 4.7 4.8 ± 0.7
Potato Starch 3.9 + 2.1 3.7 ± 2.1 2.6 ± 1.1 2.4 ± 0.9
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The next avenue to investigate was performing a dose-response assay in order to 
establish both the lowest concentration of acarbose at which growth is hindered, and at 
what concentration growth recovers in order to establish IC50 values. Specifically, it was 
decided to identify a fixed timepoint in each assay in order to consistently compare growth 
in each concentrations of acarbose versus the non-treated culture. To do this the OD600 
value corresponding to the timepoint at which the untreated culture exits its exponential 
phase, 13.5 h in pullulan and 14 h in potato starch, was chosen since this would ideally 
represent the maximum growth achievable in the environment. Since all four strains 
displayed similar growth profiles and inhibitions in previous experiments (Figures 3.2 
through 3.5), it was decided to use B. dorei JR03 as a representative strain for the dose-
response assay. Concentrations of 0.1, 0.5, 1, 5, 10, 50, and 100 μM acarbose were screened 
against B. dorei JR03 in M-RUM supplemented with either pullulan or potato starch. 
Figure 3.6 details the response of JR03 to acarbose treatment.  The data are expressed as 
both growth curves, as well as a bar graph detailing the percent growth observed at each 
concentration at the previously specified timepoint of maximum growth for the untreated 
cultures. In the presence of both potato starch and pullulan, a 90 % inhibition was 
maintained at concentrations as low as 5 μM. Starting at 1 μM to 0.5 μM concentrations of 
acarbose, growth steadily recovered with full recovery noted at 0.1 μM acarbose. 
Additionally, the doubling time of the culture was suppressed in the presence of acarbose, 
with the level of suppression increasing with acarbose concentration as seen with the 
growth curves in Figure 3.6. IC50 values were obtained from the dose-response data: 0.3 















































concentrations demonstrate that B. dorei is more susceptible to acarbose treatment, 
exhibiting lower IC50 values than those described in the previous chapter with both Bt and 






Figure 3.6: Dose response of B. dorei JR03 in either A) pullulan at 13.5 h or B) potato 
starch at 14 h. Graphs show both the percent growth and doubling time at each dose in 
either carbohydrate alongside the associated growth curves. Plots of growth data and the 
resulting line equation used to generate IC50 for each associated growth curve can be found 
in Appendix II Figure 3.A1. 
3.3 Effects of Acarbose Treatment on Growth in Potato Starch Constituents 
Potato starch comprises a mixture of 2 components, amylose and amylopectin, in a 
20:80 ratio. Amylose consists of a linear chain of glucose assembled with a-1,4-glycosidic 















































bonds at C6 that serve as branching points. While it was presumed that acarbose would 
display the same growth inhibition of Bacteroides spp. when grown in minimal media 
containing these components individually as was observed with the growth assays in 
minimal medium containing potato starch, we had not evaluated this assumption 
experimentally. It is possible that the structural differences between the two potato starch 
components might lead to differing inhibitory responses in the presence of acarbose. With 
this in mind the growth of Bt, Bf, and B. dorei JR03 was assessed over 48 h with one of the 
two components of potato starch, either amylose or amylopectin, in both the presence and 
absence of 100 µM acarbose. In order to standardize conditions for comparison of the three 
bacteria, the 96 well plate assays were all conducted in M-RUM broth. 
Figure 3.7: Structure of the two components that comprise potato starch, amylose and 
amylopectin 
(R = H, Amylose 20%) 


















Unexpectedly, each species showed selective, preferential growth in the presence of the 
two components of potato starch individually. Bt grew preferentially in amylopectin, while 
Bf preferred amylose (Figure 3.8). Interestingly, B. dorei JR03 showed no preference, and 
was able to grow consistently in both components of potato starch individually. In their 
preferred carbohydrate, each species’ growth was inhibited by acarbose in the same manner 
as previously noted in experiments with minimal media containing native potato starch (i.e. 
90% growth inhibition at 100 µM concentration of acarbose).  
At this time, these data do not seem to give any indication at an inhibitory mechanism, 
though they do offer an important glimpse into differences of the Sus system at a species 
level. Up to this point studies conducted have operated under the assumption that while our 
various Bacteroides representatives are different species, their Sus systems were relatively 
uniform and conserved between members. These data question that assumption, showing 
that the Sus systems of the respective species have diverged in a manner that allows for 
prioritization of different starch configurations. While this result is interesting, it does not 
challenge the underlying strategy of phylum-level inhibition since even with these 
divergences in Sus activity, acarbose still retains its ability to target the system leading to 
the greater than 90% inhibition of growth in the preferred potato starch component as well 
as in potato starch itself and pullulan. 
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Figure 3.8: Growth of Bt, Bf, and B. dorei JR03 in either amylose or amylopectin with and 
without the amylase inhibitor acarbose. Bt grew preferentially in amylopectin, while Bf 
preferred amylose. Regardless of the preferred potato starch component, all three species 
again displayed a 90% or better growth inhibition in the presence of 100 µM acarbose. A) 
Bt grown in M-RUM supplemented with amylose in the presence (blue) or absence (black) 
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of 100 µM acarbose. B) Bf grown in M-RUM supplemented with amylose in the presence 
(blue) or absence (black) of 100 µM acarbose. C) B. dorei JR03 grown in M-RUM 
supplemented with amylose in the presence (blue) or absence (black) of 100 µM acarbose. 
D) Bt grown in M-RUM supplemented with amylopectin in the presence (blue) or absence
(black) of 100 µM acarbose. E) Bf grown in M-RUM supplemented with amylopectin in 
the presence (blue) or absence (black) of 100 µM acarbose. F) B. dorei JR03 grown in M-
RUM supplemented with amylopectin in the presence (blue) or absence (black) of 100 µM 
acarbose.  
3.4: Conclusions 
Over the course of this chapter, the effects of acarbose on the growth of strains of the 
clinically relevant B. dorei in various glucose-based carbohydrate sources has been 
described. As seen with both Bt and Bf, acarbose demonstrates the ability to disrupt B. 
dorei growth as can be seen with inhibition in the presence of starches at a concentration 
of 100 µM. Acarbose again has no inherent effects on representative bacteria outside of 
growth in starches, which is evidenced by the lack of negative impacts seen while grown 
in the presence of glucose and maltose. Together this information shows that treatment of 
four separate strains of B. dorei with acarbose selectively inhibits their Sus system leading 
to non-lethal growth inhibition similar to that described in Chapter 2 for Bt and Bf. Due to 
B. dorei’s significance as a clinically relevant member of the Bacteroides genus, this
sensitivity further strengthens the argument that acarbose, or a structural analogue, could 
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be used as a therapeutic avenue to promote desirable shifts in the gastrointestinal 
microbiota in a phylum-specific manner. Further, sensitivity of B. dorei to acarbose is 
increased compared to that of Bt and Bf, exhibiting sub-micromolar IC50 values for this 
clinically relevant species. These factors bolster the need for continued investigations into 
the use of acarbose and the identification of its mechanism of inhibition against the Sus. 
To that end, this chapter also touched on initial experiments probing the effects of 
acarbose on the Sus-mediated degradation of both components of potato starch, amylose 
and amylopectin, with all three representative species of our target genus. These 
experiments served to identify species-dependent variations in the Sus system 
demonstrated by preferential starch utilization of each species in individual components of 
potato starch. Specifically, Bt prefers amylopectin, Bf prefers amylose, and B. dorei showed 
no preference. Taken together this information demonstrates that the Sus may not be as 
uniform across member  of the phylum as originally thought, though these variations don 





Tryptone, yeast extract, and glucose (TYG) agar and broth were prepared following 
the procedure described in the Anaerobe Laboratory Manual.7 Modified Ruminococcus 
(M-RUM) Media (100 mL) was adapted from the recipe for Ruminococcus media reported 
by Flint, et al.6, and prepared as follows: 40 mL of deionized H2O was added to 0.25 g 
tryptone, 0.0625 g yeast extract, 0.4 g NaHCO3, 0.09 g ammonium sulfate, 0.1 mg calcium 
(D)-pantothenate, 0.1 mg nicotinamide, 0.01 mg folinic acid calcium salt hydrate, 5 mL K+ 
/Na+ salt solution (4.5 g K2HPO4, 4.5 g KH2PO4, 9 g NaCl, 500 mL deionized H2O), 1 mL 
of RUM vitamin mix (1 mg biotin, 1 mg cobalamin, 3 mg p-amino benzoic acid, 5 mg folic 
acid, 15 mg pyridoxamine, 5 mg thiamine, 5 mg riboflavin, 100 mL deionized H2O), 800 
µL 1.9 mM hematin/ 0.2 M (L)-histidine solution, 500 µL 200X MgSO4 solution (0.88 g 
in 100 mL deionized H2O), 500 µL 200X CaCl2 solution (1.8 g in 100 mL deionized H2O), 
183 µL acetic acid, 67 µL propionic acid, 26.4 µL isobutyric acid, 10.8 µL valeric acid, 
and 10.8 µL isovaleric acid. The resulting solution was brought to a pH of 6.8 and 2 mL of 
100x (L)-cysteine (50 mg/mL 10mM HCl) was added. The solution was brought to a final 
volume of 100 mL, 0.5 g of the appropriate carbohydrate source was added, and the 
resulting medium was filter-sterilized.  
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96 Well Plate Growth Assay for Bacteroides dorei, Bt, and Bf 
Growth in TYG agar and broth 
B. dorei (JR01, JR02, JR03, and JR04), Bt and Bf from freezer stocks where grown
on TYG agar plates for at least 48 hours in a GasPak™ Anaerobic Jar with a BD GasPak™ 
EZ anaerobe container system and incubated at 37 ˚C. TYG overnight liquid cultures were 
prepared from these plates following the procedure described in the previous chapter.  
M-RUM overnight cultures
After incubation, M-RUM liquid cultures were prepared from 100 µL of the TYG 
overnight culture using the same procedure, but substituting M-RUM for TYG. Culture 
tubes were incubated for 18 – 24 h. at 37 ˚C.  
96 Well Plate Assay 
In an anaerobic chamber with a hydrogen level maintained at 2.0% using a gas mix 
of 85% nitrogen/10% carbon dioxide/5% hydrogen and a balance of nitrogen, 500 µL of 
the M-RUM glucose overnight culture was centrifuged at 8,000 rpm using a Chemglass 
MLX-108-CLS Mini Centrifuge for 1 min until a pellet formed and the resulting
supernatant was removed. The pellet was suspended in 500 µL of 2x M-RUM medium 
with no carbohydrate source. This suspension was used to inoculate 25 mL of 2x M-RUM 
medium. 100 µL of the inoculated medium was aliquoted into the wells of a 96 well plate, 
followed by 100 µL of the corresponding carbohydrate source at a 2x concentration or 
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deionized H2O as a control. If acarbose was being tested, it was added to the 2x 
carbohydrate source also at a 2x concentration. Plates were then inserted into a BioTek 
Epoch 2 Microplate Spectrophotometer where they were incubated at 37 ˚C for 48 h with 
a 2 ˚C gradient. During incubation, the optical density at 600 nm (OD600) was measured 
every half hour. Prior to each measurement, there was a 15 s shake. The resulting ODs 





Figure 3.A1 Dose response assay data and the resulting line equation from Figure 3.6 used 
to calculate the IC50 values. IC50 was determined by solving each equation for x where y = 
50. A) Percent growth of B. dorei JR03 in pullulan with the amylase inhibitor acarbose. B)
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EFFECTS OF ACABOSE ON GUT MICROBIOME AND DISEASE ONSET OF 
NON-OBESE DIABETIC MICE 
4.1 Introduction 
Work presented in this dissertation has thus far established that both selective and non-
lethal inhibition of the Bacteroides genus, through the targeting of the Sus system, is 
obtained with treatment by the amylase inhibitor acarbose. Greater than 90% growth 
inhibition is consistently observed in three members of the genus which are commonly 
found in the gut microbiome (GM). The inhibitory effects are evident in several strains of 
the clinically relevant organism Bacteroides dorei  isolated directly from patients suffering 
from the autoimmune condition type 1 diabetes (T1D). Highlighting the selective nature of 
acarbose-mediated Sus inhibition, very limited inhibitory effects were observed with 
members of the Firmicute phylum or with Escherichia coli, one of the more prevalent 
members of the GM. These observations serve as a proof of concept for the use of amylase 
inhibitors to inhibit the growth of select gut microbial populations as a potential therapeutic 
strategy to manipulate the gut microbiota to ameliorate diseases associated with GM 
dysbiosis. 
While the experiments presented up to this point have been vital for establishing 
acarbose as a selective inhibitor of Sus in a controlled system, they do not accurately reflect 
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the complex environment of the gut, which houses both a variety of microbes and variable 
metabolic resources depending on the host’s diet. This complexity has the potential to blunt 
any inhibitory properties possessed by acarbose that have been identified previously. For 
instance, since multiple classes of carbohydrates are obtained through the diet, and are 
therefore present in the gut, even successful, selective targeting of Sus may not ensure 
growth inhibition of the target microbial population. Other Sus-like enzyme suites could 
also be engaged that may not be hindered by acarbose in order to capture alternative 
carbohydrates, limiting or nullifying the previously observed inhibition.1 This could be 
especially problematic since experiments demonstrating acarbose’s poor inhibitory effect 
on the Sus-like construct responsible for fructan degradation discussed in chapter two 
suggests that inhibition is exclusive to starch degradation mechanisms. Additionally, while 
we have probed the effects of acarbose on a few representative GM constituents outside of 
the Bacteroidetes phylum, the colon houses many more organisms that may or may not be 
affected by acarbose, and if hindered could lead to negative effects. 
To begin addressing these concerns, we decided to investigate the effects of treatment 
with acarbose on a model organism. Such a model would allow for the first steps in gauging 
the effects of acarbose on the GM of a living organism. If acarbose-mediated alterations to 
gut microbial population was observed, it would provide the rationale for further 
investigations along these lines. Additionally, many human diseases have correlating 
animal models, including several conditions that have been associated with dysbiosis of 
the GM. If it is found that acarbose does in fact alter gut microbial populations, ideally 
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lowering Bacteroidetes constituents selectively, then such disease models would be 
integral for interrogating the possibility of amylase inhibitors for use as therapeutic 
treatments. While there are a variety of animal models that could serve for our purposes, 
murine models have long been used to fulfill this role. These models provide several 
distinct advantages such as the ability to house many participants in a single area, and their 
short lifespan allows for the observation of GM development from pups to adult in a 
reasonable timespan.  
While there are a variety of murine models available, it was decided to use one that 
also presents with a disease that has been associated with dysbiosis of the GM, specifically 
a model for the development of type 1 diabetes (T1D). This would allow not only for the 
establishment of acarbose’s ability to modulate gut populations in vivo, but also be the first 
step into evaluating whether such changes affect disease development in predisposed 
individuals. There are two common murine models for T1D, the bio-breeding rats (BBR) 
and the non-obese diabetic (NOD) murine model. Both models spontaneously develop self-
reactive immune components that disrupt blood glucose regulation, though the NOD mice 
model presented with a variety of characteristics making it more suitable for our 
investigations. While both the NOD and BBR models display insulitis mediated through a 
variety of self-reactive immune components, the BBR model is known to present with 
lymphopenia, leading to a reduction in these components in the blood system.2 
Additionally, the microbiome of NOD mice over time mirrors that found in various human 
studies, with an increase in members of the Bacteroidetes phylum and a reduction in overall 
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bacterial diversity.3,4 Because of this similarity in disease presentation, GM dysbiosis, and 
its common use in investigations between the GM and T1D, the NOD model was used for 
our analysis. 
The NOD model has a known disease incident rate with 90 % of female mice displaying 
the elevated BGLs indicative of the disease by week 30, with a median incidence of 18 
weeks.5 In contrast, the male mice belonging to this model display a much lower rate of 
disease onset. Interestingly, NOD mice have also demonstrated other links between their 
GM and the incidence of autoimmunity.  For example,  antibiotic-treated NOD pups have 
an increased rate of the disease.6,7 These findings highlight the fact that while the 
microbiome certainly is not the sole contributor to the development of T1D in this model, 
it still plays an important role in disease incidence and again suggests that alterations to 
this population could lower the risk of disease development. 
For our initial mouse study, the primary areas of investigation where as follows: Both 
5 µg/mL ( low dose) and 10 µg/mL (high dose) doses of acarbose were administered (i.e. 
ad libitum in drinking water) to mice, as well as a control group not given the treatment in 
order to see if the onset of hyperglycemia could be delayed or even prevented throughout 
the course of the study. Further, we wished to evaluate whether any changes to the 
composition of the microbiota were observed upon treatment with acarbose. Specifically, 
we were interested whether a reduction in members of the Bacteroidetes phyla would result 
in the treated cohort as compared to the control group to see if previous findings held in 
108
this more complex environment. Finally, merging the previous questions, do any observed 
changes in the gut microbiome correlate with changes in disease onset or rate of incidence? 
4.2 Methods 
 The animal study was conducted at the University of Florida Diabetes Institute in 
collaboration with Professor Mark Atkinson’s lab, and the team understands how to 
manage potentially confounding environmental factors that influence both the incidence of 
T1D in the model as well as the composition of the gut microbiota. This group has 
conducted hundreds of NOD mouse studies over the past twenty years. Groups of 20 female 
NOD mice from 9 weeks to 28 weeks post birth were given access to water treated with 
either 5 µg/mL (low dose) or 10 µg/mL (high dose) of acarbose. An additional control 
cohort of 20 mice were given untreated water, for a total of 60 mice across all three 
treatment groups. All mice in the study were female since female NOD mice exhibit a 90 
% disease incidence by week 30 (cf. 52 % disease incidence in NOD males at 30 weeks). 
While ideally both male and female participants would help account for any potential sex-
based bias, there was a concern that the lower incidence of disease rate in males would 
necessitate an unnecessary increase in participants for this pilot study. Additionally studies 
using the NOD mice model have historically used primarily female mice, and for these 
reasons it was decided to only use females as well.  
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 Mice were provided with Teklad LM-485 mouse diet, which contains 44.3% available 
carbohydrates derived from grains such as corn, oats, alfalfa, and soybeans. Because of this 
the mouse diet provides primarily plant derived polysaccharides with relatively few simple 
sugars.8 This affords the mice with a wide variety of classes of polysaccharides better 
mirroring the variable resources available in the gut, in contrast to the single polysaccharide 
model we have previously used in the in vitro analysis (i.e. only glucose or fructose based 
polysaccharides). Specifically, this allowed us to probe the ability of target Bacteroidetes 
phyla members to adapt to being challenged with acarbose, and identify if these organisms 
can compensate for disruption of Sus through reliance on other Sus-likes. 
 Mice were housed in groups of 5 in cages, and individual fecal samples were collected 
weekly and frozen in preparation for bacterial DNA isolation, PCR amplification, and 
taxonomic analysis. Blood glucose levels (BGLs) were monitored bi-weekly by collecting 
tail vein blood samples from each mouse. Mice whose blood glucose levels exceeded 250 
mg/dL were retested on the next day. Consecutive blood glucose measurements above 250 
mg/dL was taken as a clinical diagnosis of T1D, and the mouse was humanely sacrificed 
by CO2 asphyxiation. 
During the study, over 700 individual fecal samples were collected and shipped to 
Clemson University. In order to reduce the amount to a reasonable, yet still representative 
quantity for each cohort (Figure 4.1), samples from each mouse were selected from the 
following timepoints:   
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1) The first week of the study where blood glucose monitoring commenced (week 9)
and the week of T1D diagnosis (or the end of the study for surviving mice) .
2) Week 14, the midpoint of the study.
3) Week 21 taken for mice that survived past week 26, the midpoint between week 14
and 28.
4) Week 11, halfway between weeks 9 and 14.
This sampling pattern allowed for at least two sample per mouse even for mice who 
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Figure 4.1 Fecal samples per week (A) and per mouse (B). Sampling strategy allowed for 
representative quantity for each treatment group over the course of the study, and at least 
two mouse fecal samples per mouse, even for those who developed symptoms early in the 
study. 
The remaining fecal samples were stored in a –80 ˚C freezer for later analysis if 
necessary. Thus, microbial DNA was extracted and purified from 197 fecal samples using 
Zymo Research Fecal MiniPrep Kits and was then quantified using a Thermo Scientific 











PCR process, where 12 unique forward and 18 unique reverse primers were varied in order 
to give each sample an identifying barcode. Samples where then quantified using a Thermo 
Scientific Qubit 4 and sent to the University of North Carolina at Chapel Hill High-
Throughput Sequencing Facility for genomic sequencing and taxonomic evaluation. 
Bioinformatics analyses were conducted by the Huttenhower lab at Harvard University 
through the JDRF Microbiome Initiative Bioinformatics Center. 
4.3 Diabetes Onset By Week 
Below is a Kaplan-Meier curve demonstrating percent of diabetes onset for the three 
treatment cohorts by week (Figure 4.1). Both naïve and low dose mice displayed the first 
incidences of T1D at similar timepoints in the 13th and 12th week of the study, 
respectively. By week 16, half of the naïve cohort had developed T1D while the low dose 
mice reached this point by week 19. Mice given the high dose of acarbose did not show 
any incidences of T1D until week 16, the same timepoint at which half the naïve mice were 
already symptomatic. At week 21 half of the high dose mice had become positive for the 
elevated BGLs. From this point the incidence of disease in the three cohorts began to 
converge, and at week 28 each dosage grouping had a survival rate of roughly 20%. This 
timepoint marked the end of the study and any remaining mice that had survived up to this 
point were humanely euthanized.  
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Prior to taxonomic evaluations of the microbiome, there was evidence to suggest that 
treatment with the higher dose of acarbose may have delayed the onset of T1D in NOD 
mice. By the time the high dose cohort presented its first positive diabetic mouse, half of 
the naïve  cohort had already demonstrated elevated BGLs and were euthanized. 
Nonetheless treatment did not seem to confer a permanent therapeutic effect, given that by 
week 19 the incidence of disease in the high dose cohort caught up with the other two 
cohorts and all three groups had about the same percentages of surviving mice at the 
conclusion of the experiment. Nevertheless, this finding was encouraging, and seemingly 
supports one aspect of our initial hypothesis: the high dose treatment group displayed a 
delay on the onset of T1D in the NOD murine model, though the effect at the dose 
administered is both minor and transient. Follow up studies investigating higher doses of 
acarbose could help clarify the precise impact acarbose has on disease appearance in the 
NOD model, and see if this delay could be extended. 
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Figure 4.1 Kaplan-Meir curve displaying the survival rate of the naïve, low dose (5 
µg/mL), and high dose (10 µg/mL) cohorts over the course of the study. See Table 4.A6 
for the complete list of mouse BGLs used to evaluate diabetes onset. 
4.4 Taxonomic Diversity 
The taxonomic data presented below is meant to examine two areas of interest: 1) Did 
administration of either the low or high dose of acarbose change the composition of the gut 
microbiome in the murine model compared to a naïve  cohort over the course of the study?  
2) If so, do they correspond with the delay in diabetes incidence observed in the high dose
mouse cohort compared to the other treatment group? 
One thing to note prior to a discussion of the data is that the first fecal samples that 
were collected in the study are from week 9 of the study. Prior to this point there is no 
record of the gut microbe population. Because of this, any changes or discrepancies from 
birth to 9 weeks of age that may have influenced the final onset of T1D are not known. 
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Additionally the initial make-up of the microbiome after birth is also unknown. Because of 
this, the microbial composition at week 9 will serve as the starting microbiome for the 
context of the following analyses.  
Genomic sequencing of the mouse GM revealed the top 30 most prevalent operational 
taxonomic units (OTUs), which group constituents by 97% similarity of the 16s rRNA 
subunit. Figure 4.2 displays the complete list of these 30 OTUs, along with a heat map 
depicting their relative prevalence in the gut. As can be seen, the two OTUs dominating 
the GM samples belong to Lactobacillus, a genus from the Firmicute phylum, and 
Muribaculaceae, a family within the Bacteroidetes phylum. Smaller populations of other 
Firmicutes such as Ruminococcus, Clostridium, and Turicibacter were found, as well as 
various members of other phyla. Unfortunately, no Bacteroides genus members where 
identified in our genomic analysis, but the Muribaculaceae family makes an ideal stand in. 
This family is a member of the Bacteroidetes phylum that preferentially use starches for 
their primary metabolic processes.7 Additionally, recent genomic investigations have 
revealed that the protein mechanisms employed by these bacteria to utilize starches is 
analogous to the Sus found in the various Bacteroides species.9  
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Figure 4.2 Heat map detailing the 30 most common OTUs found in mouse fecal samples 
along with their relative abundance. Microbiomes are dominated by Muribaculaceae, a 
family belonging to the Bacteroidetes phyla, and Lactobacillus, a genus in the Firmicute 
phyla. 
The relative abundance of each OTU constituent identified in the treatment groups can 
be seen in Figure 4.3. Again all treatment groups are dominated by a combination of both 
Muribaculaceae and Lactobacillus OTUs, comprising over 50% of the GM. Interestingly, 
while these two OTUs are the most prevalent, the ratio of one to the other differs based on 
treatment received (Figures 4.3). Further highlighted in Figure 4.4, for both the naïve  and 
low dose cohorts, the GMs displayed a larger population of Muribaculaceae, and smaller 
contingent of Lactobacillus OTUs. This finding was reversed in the high dose cohort, 
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which presented with a majority of the Bacteroidetes phylum representative. These 
findings correspond to those described in the DIABIMMUNE Project described in chapters 
one and three, with Bacteroidetes members being in higher prevalence in patients who 
became serum positive for self-reactive antibodies. Additionally, the targeted decrease of 
this group seemingly imparted a protective effect. This also bolsters the idea that the 
Bacteroidetes phyla plays a partial role in the onset of T1D. Potential mechanisms for the 
association of increased Bacteroidetes members with T1D onset are discussed in detail in 
chapters one and three. 
With these findings, the prospect of using amylase inhibitors as a therapy for dysbiosis 
related disease has been strengthened. Not only did treatment alter gut microbiome 
composition, but this event coincided with a delay in onset of T1D in the high dose 
treatment group, though the protection imparted was not permanent. Following these 
findings, investigations with higher doses would help establish if this protective effect 
could be extended, and may further highlight any relevant changes to GM populations that 








Figure 4.3 Relative abundance of OTUs found in each sample organized by treatment 
cohort. The high dose treatment mice displayed a distinct microbiome shift compared with 
a higher relative abundance of Lactobacillus and Muribaculaceae compared to both the low 
dose and naïve cohorts. A) Relative abundance of OTU members found in fecal samples 
belonging to the high dose treatment group. B) Relative abundance of OTU members found 
in fecal samples belonging to the low dose treatment group. C) Relative abundance of OTU 






Figure 4.4 Percent abundance for the two dominant OTUs found in the taxonomic analysis 
of NOD mice fecal samples across the three treatment groups. A) Percent abundance of the 
Lactobacillus genus in the three treatment groups. B) Percent abundance of the 
Muribaculaceae family in the three treatment groups. 
4.5 Conclusions and Future Studies 
Together, the data presented in this chapter not only reinforce the idea that a 
dysbiosis characterized by elevated Bacteroidetes representatives play a causative role in 
the onset of T1D, but that a treatment that prevents or reverts such changes seemingly 
impart a slight protective effect manifested in a brief delay in the onset of T1D in the higher 
dose cohort. Treatment with 10 µg/mL of acarbose was capable of delaying the onset of 
the elevated BGLs that characterize T1D in the NOD mouse model by 3 weeks. 
































of the naïve cohort had already tested positive for the condition. Taxonomic investigations 
discovered that members of the high dose cohort displayed a similar GM makeup among 
themselves at the start of the study that was not matched in the low dose or naïve groups. 
As the experiment progressed, this similarity was lost with this event seemingly coinciding 
with the loss of the protective effect imparted by acarbose. High dose mice also displayed 
a relative lack of the Bacteroidetes member Muribaculaceae, and abundance of the 
Firmicute Lactobacillus compared to the other two treatment groups. The exact mechanism 
behind the protective effect displayed in the high dose treatment group still needs to be 
identified, but there are several likely possibilities. Ideally, acarbose is interfering with the 
starch utilization capabilities present in the Muribaculaceae family, in a similar manner as 
with the Bacteroides Sus, and imparting the non-lethal inhibition identified in chapters two 
and three. As discussed in chapter one, elevated Bacteroidetes representatives have been 
linked to detrimental impacts on host immune system training and regulation, so through 
prevention or delaying such an elevation in these populations, treatment may also delay the 
timeline for symptom onset in the NOD model. Follow up studies to this experiment could 
investigate higher doses of acarbose. 
Less ideal, but still possible, is that treatment may instead be disrupting the 
amylases produced in the mouse salivary and pancreatic glands and lead to lowered BGLs 
in the mouse unrelated to glucose regulation by pancreatic beta cells. Since the marker for 
the autoimmune response in this model is elevated BGLs, this could temporarily mask the 
loss of glucose regulation. Another possibility is that disruptions to the murine amylases 
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would impact the carbohydrates available to the microbes in the gut due to an increase in 
complex carbohydrates no longer being digested and absorbed by the mouse prior to 
arriving in the gut. With different metabolic resources now available, shifts in GM 
populations could occur unrelated to acarbose inhibition of GM constituents.  
In order to account for these possibilities, at least two more mouse studies are 
proposed. First, a similar study as the one presented in this chapter, but utilizing germ-free 
NOD mice would show if the delay in disease onset was achieved by acarbose impacting 
the murine amylases, or the bacteria in the microbiota. Second, a study with NOD mice 
with intact microbiota whereby acarbose treatment was administered by colonoscopy, or 
orally through a time release mechanism that would release acarbose only upon arriving at 
the colon would completely circumvent the risk of acarbose interfering with the various 
murine amylases. If the delay in onset was again observed in such an experiment, it would 
provide further evidence that microbial population alterations were predicated upon the 
direct interaction of acarbose with the bacteria without being influenced by changes to 
carbohydrate availability in the colon. Additional follow up studies to this experiment 
could investigate either treatment at an earlier age, or higher doses of acarbose. With the 
current high dose of 10 µg/mL administered beginning at week 9 post birth, symptom onset 
is delayed by 3 weeks but not prevented over the course of the entire study. By either 
elevating the level of acarbose to 50 or 100%, or starting treatment sooner after birth, the 
protective effect might be further extended.  
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Another area of further investigation is the concern that Sus-like systems may allow 
Bacteroidetes phyla members to recover from acarbose inhibition. The lack of permanent 
inhibition to the Muribaculaceae family may be attributed to the bacteria switching from 
the inhibited Sus, to other Sus-likes in order to compensate for the loss of starch processing, 
leading to their ability to recover from treatment. In vitro assays looking at the effect of 
acarbose with our representative Bacteroides spp. in the presence of mixed carbohydrates 
(for example 1:1 pullulan:inulin) would show how the bacteria respond in such a system. 
Additionally, taking an inhibited culture grown in starch, and transferring it to fresh media 
with a different class of carbohydrate (i.e. fructans, xylans, etc.) would identify any 
potential for the bacteria to recover from acarbose mediated Sus inhibition in the presence 
of other complex polysaccharides. 
While there are still questions that need to be addressed, the preliminary findings 
highlighted by this NOD murine model study, along with the findings in the previous 
chapters, offer a promising foundation for the use of amylase inhibitors as a therapeutic 
agent in the treatment of dysbiosis related illnesses. Initial in vitro investigations 
successfully identified an inhibitor of the Bacteroides Sus system consistent with the 
desired non-lethal manner. This finding was also identified in several strains of the 
clinically relevant species, Bacteroides dorei.  Treatment was found to be specific for the 
Bacteroides genus, not affecting representative Firmicutes, or the common GM constituent 
E. coli. NOD mice experiments suggest that this inhibition is translatable to the GM of a
living organism, a much more complex environment, and even provides preliminary 
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evidence for acarbose mediated delay in the onset of T1D in the NOD mouse model. While 
the delay in onset was not persistent throughout the study, it does show that it may be 
possible for acarbose derivatives, or other small molecule inhibitors to act as therapeutics 
for the treatment of diseases that are in part initiated by changes in the human GM. In that 
vein, the final chapter details the synthetic modification of the small molecule human 
amylase inhibitor quercetin in order to increase its solubility, making it viable for in vitro 




PCR Protocols and Primer Sequences 
NOTE:  the PCR protocols and DNA purification adapted from those provided by the 
Carrol lab (UNC Chapel Hill) who facilitated the DNA sequencing. 
DNA extraction from fecal samples 
Fecal samples where processed using a Zymo Research ZR Fecal DNA MiniPrep 
Kit™ according to the following protocol. Prior to processing, a Zymo-Spin™ IV-HRC 
Spin Filter was preprepared by snapping off the base and housing inside a collection tube 
which was subsequently centrifuged at 8,000 x g for 3 m. Frozen fecal samples where 
weighed (Table 4.A3) and transferred to ZR BashingBead™ lysis tube along with 750 µL 
of Zymo Research ZR Fecal DNA MiniPrep Kit™  lysis solution. The tube was secured in 
a Fischer Scientific Bead Mill 4 and processed for 240 s at 5 m/s followed by centrifuging 
at 10,000 x g for 1 m using a Fischer Scientific accuSpin Micro 17. A 400 µL aliquot of 
supernatant was transferred to Zymo-Spin™ IV Spin Filter housed in a 1.5 mL Eppendorf 
tube and centrifuged at 7,000 x g for 1 m. A 1.2 mL aliquot of Fecal DNA Binding Buffer 
with 0.5% v/v beta-mercaptoethanol was added to the filtrate and mixed by pipetting. An 
800 µL aliquot of this mixture was transferred to a Zymo-Spin™ IIC Column in a 
collection tube and centrifuged at 10,000 x g for 1 min. The flowthrough was discarded 
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and the remaining 800 µL of the mixture was transferred to a Zymo-Spin™ IIC Column in 
a collection tube and centrifuged at 10,000 x g for 1 min. To the column in a new collection 
tube, 200 µL of DNA Pre-Wash Buffer was added and centrifuged at 10,000 x g for 1 min. 
To the column, 500 µL of Fecal DNA Wash Buffer was added and centrifuged at 10,000 x 
g for 1 min. The column was then transferred to a 1.5 mL Eppendorf tube and 100 µL of 
DNA Elution Buffer was added to the column matrix and allowed to incubate at room 
temperature for 2 min. Purified DNA was then eluted into the 1.5 mL Eppendorf tube by 
centrifuging at 10,000 x g for 30 s. Purified DNA was then quantified using a Thermo 
Scientific NanoDrop Lite. 
PCR amplification and purification of bacterial DNA 
To a PCR tube, 26.5 µL of PCR master mix (from a Kapa2G Robust PCR kit w/ 
dNTPs: 10 µL of Kappa Enhancer 1 (5x), 10 µL of Kappa2G Buffer A (5x), 2.5 µL of 5µM  
forward primer mix, 2.5 µL of 5µM reverse primer mix, 1 µL 10 mM Kapa dNTP mix, and 
0.5 µL of 5U/µL Kapa2G Robust Taq 250 U) was added, followed by 50 µL of 100 ng/mL 
of DNA in PCR grade DI water. DNA samples were then amplified using an Eppendorf 
Mastercycler according to the parameters in Table 4.A1. Table 4.A2 details the DNA 
sequence for the three forward and three reverse primers that compose primer mixes 
127
Table 4.A1: PCR parameters for amplification of bacterial DNA extracted from mouse 
fecal samples 
Table 4.A2: DNA sequence of primers for PCR amplification. A) DNA sequence for the 
3 forward primers. B) DNA sequence for the 3 reverse primers. 
Following PCR amplification, DNA was purified in the following manner. MAGBIO High 
Prep™ PCR Reagent was brought to room temperature for 30 m and mixed by shaking. 
PCR grade DI water was brought to 55 °C in a hot water bath. After amplification, 90 µL 












for 5 min. The tube was then placed on an Invitorgen DynaMag ™ 96 side magnetic plate 
for 3 min until the magnetic beads settled at the bottom of the PCR tube, and the remaining 
solution was clear. While on the magnet, the liquid was removed, 200 µL of a 70% solution 
of ethanol in PCR grade DI water was added, and the tube was allowed to sit for 30 s on 
the magnet. Afterward the liquid was removed and another 200 µL of the 70% ethanol 
solution was added. The tube was allowed to stand on the magnet for 30 s and the liquid 
was again removed. The magnetic beads were allowed to dry for 5 min. on the magnet. The 
PCR tube was removed from the magnet and 40 µL of PRC grade DI water at 55 °C was 
added and pipetted to mix. This mixture was again placed on the magnet plate until the 
magnetic beads settled at the bottom. Once the solution was clear, the liquid containing the 
purified DNA was removed and transferred to a new PCR tube. 
PCR Dual Barcode indexing and purification of Bacterial DNA 
To a new PCR tube, 25 µL Kapa HiFi Ready Mix, 6.5 µL of 5 µM forward index primer, 
6.5 µL of 5 µM reverse index primer, 7.5 µL PCR grade DI water, and 5 µL of purified 
amplified bacterial DNA was added. DNA barcodes were then installed using an Eppendorf 
Mastercycler according to the parameters outlined in Table SA3. Table 4.A4 lists mouse 
samples by week along with the corresponding fecal sample weight and the assigned 
forward and reverse index primers. Table 4.A5 details the DNA sequence for each index 
primer. Following the indexing of bacterial DNA, samples where purified on a magnetic 
plate in the same manner as detailed after initial PCR amplification. Indexed bacterial DNA 
was then imaged on a 1% agarose gel to ensure a band at 1,500 base pairs . Afterward, 
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samples were quantified using a Thermo Scientific Qubit 4 and sent to the University of 
North Carolina at Chapel Hill High-Throughput Sequencing Facility for genomic 
sequencing and taxonomic evaluation. Bioinformatics analyses were conducted by the 
Huttenhower lab at Harvard University through the JDRF Microbiome Initiative 
Bioinformatics Center. 
Table 4.A3: PCR parameters for dual barcode indexing of bacterial DNA extracted from 
mouse fecal samples 
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Mouse Week Fecal Sample Weight (g) Forward Barcode Reverse Barcode
1 9 0.062 F1 R1
14 0.0631 F1 R2
21 0.0784 F1 R3
28 0.1105 F1 R4
2 9 0.0278 F1 R5
11 0.0381 F1 R6
13 0.1285 F1 R7
3 9 0.0456 F1 R8
14 0.0922 F1 R9
21 0.0445 F1 R10
27 0.0437 F1 R11
4 10 0.0356 F1 R12
14 0.1047 F1 R13
15 0.0753 F1 R14
5 9 0.0333 F1 R15
14 0.0407 F1 R16
17 0.0486 F1 R17
6 9 0.0299 F1 R18
14 0.0262 F2 R1
21 0.0624 F2 R2
27 0.0342 F2 R3
7 9 0.0186 F2 R4
11 0.0818 F2 R5
12 0.0138 F2 R6
8 9 0.0333 F2 R7
14 0.0466 F2 R8
25 0.0539 F2 R9
9 9 0.0323 F2 R10
14 0.0504 F2 R11
21 0.0556 F2 R12
28 0.1190 F2 R13
10 9 0.0276 F2 R14
11 0.0616 F2 R15
14 0.0310 F2 R16
11 10 0.0156 F2 R17
14 0.0143 F2 R18
12 10 0.0338 F3 R1
14 0.0349 F3 R2
16 0.1003 F3 R3
13 9 0.0325 F3 R4
14 0.0364 F3 R5
21 0.0813 F3 R6
28 0.0833 F3 R7
14 9 0.0225 F3 R8
14 0.0213 F3 R9
15 0.0222 F3 R10
15 10 0.0514 F3 R11
14 0.0302 F3 R12
16 0.0263 F3 R13
A)
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Mouse Week Fecal Sample Weight (g) Forward Barcode Reverse Barcode
16 10 0.0196 F3 R14
11 0.0485 F3 R15
13 0.0371 F3 R16
17 9 0.0295 F3 R17
14 0.0594 F3 R18
25 0.0507 F4 R1
18 9 0.0244 F4 R2
14 0.0622 F4 R3
15 0.0345 F4 R4
19 12 0.0274 F12 R2
15 0.0297 F12 R3
22 0.1357 F12 R4
27 0.0809 F12 R5
20 10 0.0389 F12 R6
15 0.0752 F12 R7
22 0.0704 F12 R8
21 10 0.0519 F12 R9
12 0.1095 F12 R10
22 11 0.0700 F4 R15
14 0.0453 F4 R16
21 0.0232 F4 R17
28 0.0274 F4 R18
23 10 0.0804 F12 R11
13 0.0707 F12 R12
24 9 0.0444 F5 R4
14 0.0610 F5 R5
21 0.0593 F5 R6
25 9 0.0408 F5 R7
11 0.0209 F5 R8
26 9 0.0113 F5 R9
14 0.0391 F5 R10
21 0.0645 F5 R11
28 0.0546 F5 R12
27 9 0.0504 F5 R13
14 0.0427 F5 R14
18 0.0692 F5 R15
28 9 0.0191 F5 R16
14 0.0700 F5 R17
21 0.0417 F5 R18
28 0.0708 F6 R1
29 10 0.0495 F6 R2
14 0.1005 F6 R3
17 0.0825 F6 R4
30 10 0.0165 F6 R5
14 0.0280 F6 R6
18 0.0561 F6 R7
B)
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Mouse Week Fecal Sample Weight (g) Forward Barcode Reverse Barcode
31 9 0.0200 F6 R8
14 0.0198 F6 R9
21 0.0645 F6 R10
28 0.0683 F6 R11
32 9 0.0314 F6 R12
13 0.0241 F6 R13
14 0.0251 F6 R14
33 9 0.0399 F6 R15
14 0.0291 F6 R16
21 0.0303 F6 R17
28 0.0418 F6 R18
34 10 0.0213 F7 R1
14 0.0289 F7 R2
16 0.0766 F7 R3
35 10 0.016 F7 R4
14 0.0302 F7 R5
19 0.0275 F7 R6
36 9 0.0302 F7 R7
14 0.0178 F7 R8
19 0.0758 F7 R9
37 9 0.0311 F7 R10
14 0.0586 F7 R11
23 0.0428 F7 R12
38 9 0.0671 F7 R13
14 0.0660 F7 R14
24 0.0892 F7 R15
39 9 0.0347 F7 R16
14 0.0382 F7 R17
17 0.0611 F7 R18
40 9 0.0282 F8 R1
14 0.0434 F8 R2
19 0.0228 F8 R3
41 9 0.0104 F8 R4
14 0.0318 F8 R5
21 0.0262 F8 R6
28 0.0245 F8 R7
42 9 0.0157 F8 R8
14 0.0622 F8 R9
21 0.0370 F8 R10
26 0.0347 F8 R11
43 9 0.0428 F8 R12
14 0.0946 F8 R13
25 0.0950 F8 R14
44 9 0.0577 F8 R15
14 0.0457 F8 R16
23 0.0661 F8 R17
45 10 0.0334 F8 R18
13 0.0134 F9 R1
18 0.0650 F9 R2
C)
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Table 4.A4: PCR information for dual barcode indexing of samples. A) Fecal weight and 
assigned forward and reverse primers for mice 1 – 15. B) Fecal weight and assigned 
forward and reverse primers for mice 16 – 30. C) Fecal weight and assigned forward and 
reverse primers for mice 31 – 45. D) Fecal weight and assigned forward and reverse primers 
for mice 46 – 60.  
D) Mouse Week Fecal Sample Weight (g) Forward Barcode Reverse Barcode
46 9 0.0242 F9 R3
14 0.0638 F9 R4
17 0.0713 F9 R5
47 9 0.0146 F9 R6
14 0.0772 F9 R7
18 0.1574 F9 R8
48 9 0.0273 F9 R9
11 0.0643 F9 R10
14 0.0524 F9 R11
16 0.0705 F9 R12
49 9 0.0436 F9 R13
14 0.0294 F9 R14
18 0.1351 F9 R15
50 12 0.0414 F9 R16
14 0.0871 F9 R17
21 0.0394 F9 R18
28 0.0939 F10 R1
51 9 0.103 F10 R2
14 0.0385 F10 R3
15 0.0327 F10 R4
52 9 0.0359 F10 R5
14 0.0721 F10 R6
21 0.0556 F10 R7
28 0.0913 F10 R8
53 9 0.0716 F10 R9
14 0.0401 F10 R10
21 0.1073 F10 R11
28 0.0619 F10 R12
54 9 0.0696 F10 R13
14 0.0827 F10 R14
21 0.1205 F10 R15
55 11 0.0216 F10 R16
14 0.0545 F10 R17
18 0.0549 F10 R18
56 9 0.0494 F11 R1
11 0.0456 F11 R2
14 0.0477 F11 R3
16 0.0545 F11 R4
57 9 0.0612 F11 R5
12 0.0313 F11 R6
14 0.0399 F11 R7
15 0.0286 F11 R8
58 9 0.0559 F11 R9
11 0.0540 F11 R10
14 0.0634 F11 R11
15 0.0353 F11 R12
59 9 0.0355 F11 R13
11 0.0966 F11 R14
25 0.1227 F11 R15
60 9 0.0618 F11 R16
14 0.0476 F11 R17
21 0.1033 F11 R18




Table 4.A5: DNA sequence for dual barcode indexing of PCR samples. A) DNA sequence 
for the 12 forward index primers. B) DNA sequence for the 18 reverse index primers. 








































Mouse 1 2 3 4 5 6 7 8 9 10
CAGE # 725 725 725 725 725 726 726 726 726 726
WEEK 9 BGL (mg/dL) 88 100 101 101 135 100 105 96 126 124
WEEK 10 BGL (mg/dL) 107 99 116 120 91 94 120 135 114 109
WEEK 11 BGL (mg/dL) 168 158 144 144 131 145 150 141 142 120
WEEK 12 BGL (mg/dL) 138 157 123 106 148 182 251 / 386 120 124 130
WEEK 13 BGL (mg/dL) 139 293/250 155 175 129 121 NA 165 110 189
WEEK 14 BGL (mg/dL) 133 NA 188 177 167 111 NA 127 101 399 / 394
WEEK 15 BGL (mg/dL) 122 NA 139 508 / 349 186 19 NA 126 116 NA
WEEK 16 BGL (mg/dL) 145 NA 188 NA 478 / 217 133 NA 89 110 NA
WEEK 17 BGL (mg/dL) 104 NA 113 NA 414 / 414 124 NA 95 118 NA
WEEK 18 BGL (mg/dL) 128 NA 121 NA NA 142 NA 117 132 NA
WEEK 19 BGL (mg/dL) 111 NA 150 NA NA 117 NA 149 114 NA
WEEK 20 BGL (mg/dL) 111 NA 132 NA NA 158 NA 148 111 NA
WEEK 21 BGL (mg/dL) 109 NA 197 NA NA 103 NA 100 116 NA
WEEK 22 BGL (mg/dL) 82 NA 227 NA NA 107 NA 112 121 NA
WEEK 23 BGL (mg/dL) 121 NA 172 NA NA 220 NA 124 136 NA
WEEK 24 BGL (mg/dL) 95 NA 186 NA NA 119 NA 130 111 NA
WEEK 25 BGL (mg/dL) 111 NA 181 NA NA 132 NA 409 / 491 120 NA
WEEK 26 BGL (mg/dL) 134 NA 199 NA NA 232 NA NA 196 NA
WEEK 27 BGL (mg/dL) 114 NA 399 / 443 NA NA 402 / 405 NA NA 240 NA
WEEK 28 BGL (mg/dL) 98 NA NA NA NA NA NA NA 505 NA
Mouse 11 12 13 14 15 16 17 18 19 20
CAGE # 724 724 724 724 724 723 723 723 723 723
WEEK 9 BGL (mg/dL) 106 97 117 105 116 111 87 103 110 146
WEEK 10 BGL (mg/dL) 101 112 178 98 97 79 95 96 92 132
WEEK 11 BGL (mg/dL) 148 149 148 134 133 114 145 141 163 113
WEEK 12 BGL (mg/dL) 108 108 140 117 99 95 102 137 108 114
WEEK 13 BGL (mg/dL) 117 145 108 135 122 252 / 331 121 117 135 64
WEEK 14 BGL (mg/dL) 112 99 120 138 110 NA 112 157 107 133
WEEK 15 BGL (mg/dL) 326 187 114 284 / 432 159 NA 85 391 / 256 97 115
WEEK 16 BGL (mg/dL) NA 347 / 390 105 NA 359 / 265 NA 123 NA 146 145
WEEK 17 BGL (mg/dL) NA NA 122 NA NA NA 129 NA 100 111
WEEK 18 BGL (mg/dL) NA NA 110 NA NA NA 125 NA 95 206
WEEK 19 BGL (mg/dL) NA NA 122 NA NA NA 77 NA 104 203
WEEK 20 BGL (mg/dL) NA NA 123 NA NA NA 159 NA 135 282 / 174
WEEK 21 BGL (mg/dL) NA NA 124 NA NA NA 149 NA 119 233
WEEK 22 BGL (mg/dL) NA NA 128 NA NA NA 122 NA 169 338 / 195
WEEK 23 BGL (mg/dL) NA NA 116 NA NA NA 114 NA 206 412 / 391
WEEK 24 BGL (mg/dL) NA NA 125 NA NA NA 214 NA 111 NA
WEEK 25 BGL (mg/dL) NA NA 145 NA NA NA 405 / 530 NA 91 NA
WEEK 26 BGL (mg/dL) NA NA 128 NA NA NA NA NA 98 NA
WEEK 27 BGL (mg/dL) NA NA 130 NA NA NA NA NA 108 NA
WEEK 28 BGL (mg/dL) NA NA 109 NA NA NA NA NA 101 NA
Mouse 21 22 23 24 25 26 27 28 29 30
CAGE # 722 722 722 722 722 721 721 721 721 721
WEEK 9 BGL (mg/dL) 84 118 97 97 121 98 91 95 91 105
WEEK 10 BGL (mg/dL) 108 119 91 99 114 108 64 128 99 109
WEEK 11 BGL (mg/dL) 161 113 175 158 265 / 467 107 155 131 131 157
WEEK 12 BGL (mg/dL) 178 120 144 137 NA 114 98 123 164 116
WEEK 13 BGL (mg/dL) 345 485 139 159 133 NA 161 11 135 92 112
WEEK 14 BGL (mg/dL) NA 98 376 / 482 114 NA 108 184 118 104 136
WEEK 15 BGL (mg/dL) NA 102 NA 140 NA 114 147 117 127 129
WEEK 16 BGL (mg/dL) NA 136 NA 128 NA 101 176 124 392 / 180 218
WEEK 17 BGL (mg/dL) NA 101 NA 131 NA 139 237 131 522 / 699 265 / 161 
WEEK 18 BGL (mg/dL) NA 104 NA 164 NA 133 553 / 545 95 NA 513 / 704
WEEK 19 BGL (mg/dL) NA 131 NA 157 NA 204 NA 180 NA NA
WEEK 20 BGL (mg/dL) NA 230 NA 178 NA 124 NA 115 NA NA
WEEK 21 BGL (mg/dL) NA 129 NA 333 / 365 NA 143 NA 82 NA NA
WEEK 22 BGL (mg/dL) NA 89 NA NA NA 130 NA 107 NA NA
WEEK 23 BGL (mg/dL) NA 120 NA NA NA 165 NA 99 NA NA
WEEK 24 BGL (mg/dL) NA 103 NA NA NA 120 NA 98 NA NA
WEEK 25 BGL (mg/dL) NA 111 NA NA NA 192 NA 104 NA NA
WEEK 26 BGL (mg/dL) NA 107 NA NA NA 171 NA 96 NA NA
WEEK 27 BGL (mg/dL) NA 88 NA NA NA 205 NA 98 NA NA





Figure 4.A6: Cage number and blood glucose levels (BGLs) for mouse treatment groups. 




Mouse 31 32 33 34 35 36 37 38 39 40
CAGE # 720 720 720 720 720 719 719 719 719 719
WEEK 9 BGL (mg/dL) 98 122 105 132 110 109 115 122 114 112
WEEK 10 BGL (mg/dL) 103 110 135 91 108 109 131 133 148 109
WEEK 11 BGL (mg/dL) 118 90 164 154 144 142 181 224 139 173
WEEK 12 BGL (mg/dL) 109 136 135 128 134 93 133 121 118 129
WEEK 13 BGL (mg/dL) 118 147 109 110 86 92 61 87 78 147
WEEK 14 BGL (mg/dL) 109 326 / 366 110 140 96 106 154 127 124 152
WEEK 15 BGL (mg/dL) 104 NA 93 223 110 120 144 118 120 130
WEEK 16 BGL (mg/dL) 151 NA 156 439 / 405 136 120 123 122 203 112
WEEK 17 BGL (mg/dL) 113 NA 107 NA 138 195 130 159 614 / 515 162
WEEK 18 BGL (mg/dL) 124 NA 99 NA 205 167 100 134 NA 184
WEEK 19 BGL (mg/dL) 143 NA 89 NA 325 / 277 449 / 524 133 151 NA 445 / 445
WEEK 20 BGL (mg/dL) 190 NA 108 NA NA NA 126 140 NA NA
WEEK 21 BGL (mg/dL) 151 NA 142 NA NA NA 132 144 NA NA
WEEK 22 BGL (mg/dL) 178 NA 149 NA NA NA 155 168 NA NA
WEEK 23 BGL (mg/dL) 175 NA 180 NA NA NA 383 / 459 152 NA NA
WEEK 24 BGL (mg/dL) 193 NA 100 NA NA NA NA 295 / 315 NA NA
WEEK 25 BGL (mg/dL) 203 NA 104 NA NA NA NA NA NA NA
WEEK 26 BGL (mg/dL) 185 NA 180 NA NA NA NA NA NA NA
WEEK 27 BGL (mg/dL) 165 NA 125 NA NA NA NA NA NA NA
WEEK 28 BGL (mg/dL) 178 NA 186 NA NA NA NA NA NA NA
Mouse 41 42 43 44 45 46 47 48 49 50
CAGE # 718 718 718 718 718 717 717 717 717 717
WEEK 9 BGL (mg/dL) 85 106 96 120 119 104 96 164 120 157
WEEK 10 BGL (mg/dL) 92 131 109 112 123 92 114 107 144 111
WEEK 11 BGL (mg/dL) 84 144 100 128 152 116 121 99 111 129
WEEK 12 BGL (mg/dL) 101 121 122 97 103 123 121 112 108 111
WEEK 13 BGL (mg/dL) 108 125 111 111 112 132 205 135 111 113
WEEK 14 BGL (mg/dL) 111 120 148 148 110 133 136 178 125 85
WEEK 15 BGL (mg/dL) 154 152 131 132 218 151 176 186 154 86
WEEK 16 BGL (mg/dL) 140 97 103 111 159 343 / 164 146 504 / 394 222 113
WEEK 17 BGL (mg/dL) 120 115 121 122 239 333 / 587 182 NA 258 / 240 109
WEEK 18 BGL (mg/dL) 144 75 122 116 585 / 504 NA 446 / 482 NA 529 / 566 109
WEEK 19 BGL (mg/dL) 137 118 149 142 NA NA NA NA NA 149
WEEK 20 BGL (mg/dL) 202 159 237 125 NA NA NA NA NA 212
WEEK 21 BGL (mg/dL) 144 152 127 150 NA NA NA NA NA 190
WEEK 22 BGL (mg/dL) 130 165 141 189 NA NA NA NA NA 158
WEEK 23 BGL (mg/dL) 150 246 155 384 / 303 NA NA NA NA NA 182
WEEK 24 BGL (mg/dL) 105 173 143 NA NA NA NA NA NA 138
WEEK 25 BGL (mg/dL) 114 211 288 / 317 NA NA NA NA NA NA 137
WEEK 26 BGL (mg/dL) 127 223 NA NA NA NA NA NA NA 147
WEEK 27 BGL (mg/dL) 144 484 / 437 NA NA NA NA NA NA NA 316 / 244
WEEK 28 BGL (mg/dL) 175 NA NA NA NA NA NA NA NA 290
Mouse 51 52 53 54 55 56 57 58 59 60
CAGE # 716 716 716 716 716 715 715 715 715 715
WEEK 9 BGL (mg/dL) 92 113 96 119 135 123 106 102 111 120
WEEK 10 BGL (mg/dL) 143 152 97 120 143 119 125 107 112 126
WEEK 11 BGL (mg/dL) 119 142 112 123 133 124 131 119 143 117
WEEK 12 BGL (mg/dL) 136 152 181 177 151 130 140 117 105 120
WEEK 13 BGL (mg/dL) 113 90 100 104 125 113 156 113 130 93
WEEK 14 BGL (mg/dL) 98 109 109 105 133 131 216 138 117 143
WEEK 15 BGL (mg/dL) 155 240 155 166 157 158 546 / 604 395 / 414 104 149
WEEK 16 BGL (mg/dL) 138 126 173 196 156 523 / 578 NA NA 113 138
WEEK 17 BGL (mg/dL) 99 94 95 104 235 NA NA NA 139 110
WEEK 18 BGL (mg/dL) 195 172 151 161  733 / 592 NA NA NA 118 119
WEEK 19 BGL (mg/dL) 113 124 124 125 NA NA NA NA 123 157
WEEK 20 BGL (mg/dL) 101 114 114 172 NA NA NA NA 119 119
WEEK 21 BGL (mg/dL) 127 108 108 467 / 441 NA NA NA NA 144 120
WEEK 22 BGL (mg/dL) 147 143 157 NA NA NA NA NA 195 110
WEEK 23 BGL (mg/dL) 152 125 156 NA NA NA NA NA 225 135
WEEK 24 BGL (mg/dL) 443 / 240 224 107 NA NA NA NA NA 219 123
WEEK 25 BGL (mg/dL) 510 / 296 236 181 NA NA NA NA NA 268 / 347 111
WEEK 26 BGL (mg/dL) NA 192 178 NA NA NA NA NA NA 121
WEEK 27 BGL (mg/dL) NA 159 166 NA NA NA NA NA NA 113
WEEK 28 BGL (mg/dL) NA 361 220 NA NA NA NA NA NA 149
137
Cage number and BGLs for mice 11 – 20 belonging to the naïve treatment group. C) Cage 
number and BGLs for mice 21 – 30 belonging to the low dose treatment group. D) Cage 
number and BGLs for mice 31 – 40 belonging to the low dose treatment group. E) Cage 
number and BGLs for mice 41 – 50 belonging to the high dose treatment group. F) Cage 
number and BGLs for mice 51 – 60 belonging to the high dose treatment group. NA: Mice 
whose BGLs exceeded 250 twice on the same day where sacrificed, and data was 
unavailable past this point. 
Sequencing Data Analysis 
A median of 67,984 (average 77,306) reads per sample were obtained. Data analysis was 
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 CHAPTER 5: SYNTHETIC MODIFICATIONS OF QUERCETIN 
5.1 Introduction 
As described in Chapter 4, while in vitro studies revealed that acarbose is a potent 
inhibitor of the Sus system, this effect was not as drastic as hoped in the NOD mice model, 
only offering a slight delay in onset of symptoms of T1D. In order to identify more potent 
therapeutics, the next phase of this project will focus on the evaluation of other molecular 
scaffolds with similar potency against the Bacteroides Sus. The rationale for this endeavor 
is two-fold. First, we are seeking scaffolds that are more amenable to medicinal chemistry. 
Secondly, an ideal compound would possess potent activity against the Sus, but lack 
potentially confounding activity against mammalian amylases, a well-known biological 
activity of acarbose. The flavonoid quercetin is a known amylase inhibitor that might be 
active against the Bacteroides Sus, yet it was initially found to be incompatible with testing 
conditions due to its poor solubility.  This chapter describes the synthetic modification of 
quercetin to improve its aqueous solubility using two independent synthetic strategies.  
Apart from acarbose, the majority of compounds tested in Chapter 2 showed no 
inhibitory activity towards Bacteroides thetaiotaomicron, and were therefore eliminated 
from further investigations. The flavonoids quercetin and rutin (Figure 5.1) however, were 
found to be insoluble in water, even when pre-dissolved in DMSO or ethanol, and therefore 
not suited for testing in minimal media assays. Since quercetin has been repeatedly 
identified as an inhibitor of human amylases,1–3 it was decided to investigate routes that 
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would impart increased solubility, thus allowing for assays with Sus containing 
Bacteroides spp. 
Beyond human amylase inhibition, quercetin has been shown to possess a variety 
of other biological activitties such as antioxidant,4–6 antihypertensive,7 and anti-
inflammatory properties6 making it a heavily investigated small molecule for therapeutic 
use. Due to this, several avenues to increase quercetin’s solubility, including synthetic 
modification,8,9 co-crystallization,10 micelle encapsulation,11–13 and the production of 
quercetin-derived prodrugs14–16 have been reported.17 While synthetic alterations may 
initially seem challenging owing to the presence of multiple phenolic OH groups, 
alkylation studies on quercetin have revealed that each hydroxyl group possesses differing 
reactivity. This difference allows for the ability to control the level of functionalization at 
these synthetic handels.8,9,18 With the use 3.5 equivalents of benzyl bromide relative to 
quercetin, compounds possessing unprotected hydroxyl groups at both C5 and C3’ (V-5) 
or exclusively at C5 (V-6) could be produced (Figure 5.2).9 Using this method, the authors 
constructed various functionalized quercetin derivatives with accompanying enhancements 
to their solubility. Using a similar procedure, it was decided to pursue a novel quercetin 
derivative bearing an N,N-dimethyl ethylamine appendage at the C5 position (V-3). It was 
thought that this functional group would allow for increased solubility through ionization 
to the positively charged ammonium in solution. Employment of the less reactive tertiary 
amine compared a primary or secondary amine would also help reduce the possibility of 





















association with charged portions of the various components of Sus. In addition, the 
previously reported derivative featuring a carboxylic acid at the C5 position (V-4)9 is 
currently being synthesized in order to provide an additional derivative for biological 
assays. 
Figure 5.1 Structures of quercetin (V-1) and rutin (V-2), as well as the N,N-dimethyl 
ethylamine (V-3) and carboxylic acid (V-4) derivatives of quercetin. 












































5.2 Synthesis of Quercetin Derivative V-3 
Compound V-6, featuring a single unprotected hydroxyl group at the C5 position, 
was synthesized in a 60% yield through the reaction of quercetin with 4 equivalents of 
benzyl bromide and K2CO3. The N,N-dimethyl ethylamine was then installed at the free 
hydroxyl group providing V-7 in 79% yield. Finally, the benzyl protecting groups were 
removeld using Pd(OH)2/C under a hydrogen atmosphere, affording the desired compound 
V-3 in quantitative yield (Figure 5.3). It was found that V-3 was still insoluble in water at
the desired concentration of 10 mM. Nonetheless, it was soluble in DMSO at the same 
concentration, and upon addition of 50 µL of the 10mM solution to 2.5 mL of water, V-3 
remained in solution resulting in a concentration of 200 µM. This solution could then be 
used in the minimal media assays initially outlined in Chapter 2.  
 
 





































reflux 65 ∘C, 24 h





5.3 Effects of V-3 on Sus Containing Bacteroidetes Representatives 
Compound V-3 was screened against Bacteroides thetaiotaomicron (Bt) and 
Bacteroides fragilis (Bf) at 100 µM of V-3 in minimal media supplemented with either 
glucose or potato starch over the course of 48 h to probe for the presence of Sus dependent 
inhibition (Figure 5.4). As described in Chapter 2, Sus mediated inhibition would be 
signified by no impact on growth in the presence of glucose, while observing inhibition in 
minimal medium containing potato starch. Additionally, since V-3 needed to be pre-
dissolved in DMSO, a vehicle control was included using the same volume of DMSO (50 
µL). Treated cultures of both Bt and Bf in glucose minimal medium showed an increase in 
doubling time of 62 ± 29 min and 54 ± 16 min compared to the untreated cultures. Only Bf 
showed a similar shift in potato starch, with an increase in doubling time of 89 ± 4 min. 
For Bt in potato starch there was an increase in the lag time of 8 ± 2 h compared to the 
untreated culture, but no meaningful impact on doubling time. While these growth 
alterations are interesting, they lack the drastic impact observed with acarbose at the same 
concentration. Further, by the conclusion of the 48 h timeframe the treated cultures 
achieved similar densities as the untreated ones (Figure 5.4). Deviations from the untreated 
culture were also found in the monosaccharide glucose demonstrating a lack of selectivity 







Figure 5.4 Growth of Bt and Bf in minimal media supplemented with either glucose or 
potato starch in untreated media (black), or challenged with either 50 µL DMSO (red) or 
100 µM V-3 (green). While the effects on growth are not as drastic as those seen with 
acarbose at the same concentration, increases in both lag time and doubling time were 
observed. A) Growth of Bt in minimal media supplemented with glucose. B) Growth of Bt 
in minimal media supplemented with potato starch. C) Growth of Bf in minimal media 
supplemented with glucose. D) Growth of Bf in minimal media supplemented with potato 
starch. 
The limited growth impact and lack of selectivity make V-3 a non-ideal candidate 
for use as a Sus-targeting therapeutic. Currently assays against Ruminococcus bromii, a 











































selective effects the compound may have on other members of the gut microbiome. 
Additionally the carboxylic acid derivative V-4 is currently being synthesized and will be 
screened in the same manner as V-3. While overall these experiments do not seem to reveal 
quercetin derivatives as promising candidates for the types of therapies being sought, the 
novel compound V-3 was successfully synthesized with the desired increased solubility 
making it more amenable to microbiological testing methods.  
5.4 Conclusions 
The modifications presented in this chapter represent the first steps into attempts at 
identifying new small molecule inhibitors of Sus and contributes to a nascent push by our 
groups screening small molecule cores for this application. This area is being actively 
pursued in single molecule in vitro screens as well as future plans for computational 
screening of therapeutic libraries against specific Sus components. While the successful 
synthesis of V-3 allowed for screens against our model organisms, the work presented 
throughout this manuscript demonstrates that acarbose is still the most successful Sus 
inhibitor to date. Acarbose displayed selective and non-lethal inhibition against Sus 
containing Bacteroidetes, did not impact the growth of other common gut microbes, and 
even alters the make-up of the gut microbiome of NOD mice as well as delays the onset of 
their symptoms. While the protective effect on NOD mice was not permanent, it showed 
that with the right small molecule inhibitor there is the potential to alleviate such 
conditions. These findings lay the groundwork for the use of small molecule therapeutics 
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to address changes in gut microbiome compositions that occur prior to and seemingly play 
a causative roll in the onset of diseases, especially those mediated by an autoimmune 
response. With the outsized role that this microbial cohort has on the health and well-being 
of their hosts, the list of potential diseases that such a treatment could relieve is large and 
continually growing. The potential behind this work, and associated projects has also left 
plenty of work still to be done, with mechanistic insight and searches for new small 




Synthesis of V-3 
3,7-Bis(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-
hydroxy-4H-chromen-4-one (V-6): Quercetin dihydrate 
(0.250 g, 0.740 mmol, 1 equiv.) and K2CO3 (0.414 g, 2.960 
mmol, 4 equiv.) where taken up in 10 mL of DMF (anhyd.) in a 100 mL round bottom 
flask.  Benzyl bromide (356 µL, 2.960 mM, 4 equiv.) was added under an argon 
atmosphere. The reaction mixture was stirred at 0 °C for 2 h,  allowed to return to room 
temperature, and stirred for and additional 24 h. The reaction mixture was then diluted with 
25 mL of ethyl acetate and washed three times with DI water. The organic layer was dried 
over anhydrous sodium sulfate. The solvent was removed by rotary evaporation. The 
resulting solid was purified using flash chromatography on silica gel with 80:20 
hexanes:ethyl acetate to give V-6 as a yellow solid with a 60% yield. 
1H NMR: (300 MHz, CDCl3); δ 12.72 (s ,1H), δ 7.74 (d, 1H), δ 7.58 (dd, 1H), δ 7.51 – 
7.25 (m, 20H), δ 6.99 (d, 1H), δ 6.48 (dd, 2H), δ 5.28 (s, 2H), δ 5.16 (s, 2H), δ 5.07 (s, 2H), 
δ 5.02 (s, 2H); 13C{1H} NMR: (75 MHz, CDCl3) δ 178.8, 164.5, 162.1, 156.7, 156.4, 151.1, 
148.2, 137.5, 136.9, 136.7, 136.4, 135.8, 128.8, 128.8, 128.6, 128.5, 128.4, 128.3, 128.0, 
127.9, 127.5, 127.4, 127.2, 123.4, 122.6, 115.3, 113.7, 106.2, 98.6, 93.1, 77.2, 74.4, 71.1, 















Compound V-6 (0.300 g, 0.453 mmol, 1 equiv.) and K2CO3 (0.190 
g, 1.359 mmol, 3 equiv.) where taken up in 10 mL of acetone 
(anhyd.) in a 100 mL 3-neck round bottom flask. Next, 2-chloro-N,N-dimethylethylamine 
hydrochloride (0.200 g, 1.359 mmol, 3 equiv.) was added under an argon atmosphere. This 
mixture was then refluxed at 65 °C for 24 h under an argon atmosphere. The cooled reaction 
mixture was then diluted with 25 mL of ethyl acetate and washed three times with DI water. 
The organic layer was dried over sodium sulfate and the solvent was removed by rotory 
evaporation. The resulting solid was purified using flash chromatography on silica gel 
using 90:10 DCM:methanol to give V-7 as an off white-solid with a 79 % yield. 
1H NMR: (300 MHz, CDCl3); δ 7.72 (d, 1H), δ 7.54 (dd, 1H), δ 7.50 – 7.23 (m, 23H), δ 
6.97 (d, 1H), δ 6.53 (dd, 2H), δ 5.26 (s, 2H), δ 5.16 (s, 2H), δ 5.04 (s, 2H), δ 4.97 (s, 2H); 
δ 4.40 (t, 2H), δ 3.32 (t, 2H), δ 2.77 (s, 6H);  13C{1H} NMR: (75 MHz, CDCl3) δ 178.8,  
173.9, 162.9, 159.2, 158.6, 153.6, 150.6, 148.2, 139.6, 137.0 136.8, 136.8, 135.6, 128.8, 
128.8, 128.8, 128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.9, 127.6, 
127.5, 127.4, 127.2, 123.7, 122.2, 115.1, 113.7, 109.6, 97.8, 94.4, 74.2, 71.0, 70.9, 70.6, 
66.3, 57.1, 45.2, 31.0, 29.7, 29.7; FT-IR: (neat) 𝝊 (cm-1) 2922.2, 1624.1, 1599.0 1494.8, 
1452.4, 1427.3, 1321.2, 1192.0, 1166.9, 1107.1, 1022.3, 731.0, 694.4; HRMS: [M+H]+
















1-yl)ethoxy))-4H-chromen-4-one (V-3): Compound V-7 (0.139 g,
0.190 mM, 1 equiv.) and Pd(OH)2/C  (0.018 g, 0.019 mM, 10 mol %) 
were taken up in 5 mL of a 1:1 mixture of THF:ethanol in a 100 mL 
round bottom flask.  The mixture was stirred under a hydrogen atmosphere (balloon) at 
room temperature for 4 h.  The reaction was filtered through a bed of celite and the solvent 
was removed by rotory evaporation. The resulting residue was purified with reverse phase 
flash chromatography using C18 reverse phase silica with 25:75 DI water:acetonitrile 
(0.1% TFA) resulting in a yellow solid with an 100% yield. 
1H NMR: (300 MHz, DMSO) δ 10.98 (s, 1H), δ 10.06 (s, 1H), δ 9.54 (s, 1H), δ 9.29 (s, 
1H), 8.82 (s, 1H), δ 7.65 (d, 1H), δ 7.51 (dd, 1H), δ 6.89 (d, 1H), δ 6.58 (d, 1H), δ 6.47 (d, 
1H), δ 4.43 (t, 2H), δ 3.57 (t, 2H), δ 3.02 (s, 6H); 13C{1H} NMR: (75 MHz, DMSO) δ 
171.9, 163.1, 159.0, 158.3, 147.8, 145.7, 143.3, 137.8, 122.7, 119.9, 116.2, 115.2, 106.0, 
98.5, 96.2, 65.0, 56.4, 44.3, 31.3; FT-IR: (neat) 𝝊 (cm-1) 3080.3, 2737.0, 1770.7, 1680.0, 
1606.7, 1504.5, 1423.5, 1373.3, 1325.1, 1180.4, 1134.1, 1101.4, 997.2, 927.8, 837.1, 
787.0, 723.3, 611.4; HRMS: [M+H]+ Calculated for C19H20NO7: 374.1240, found: 















96 Well Plate Growth Assays For Bt and Bf 
Bacterial cultures and 96 well plate assay for Bt and Bf were conducted as described in 
chapter two appendix II: Supplemental Procedures. 
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